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ABSTRACT 
Cytotoxic T lymphocytes (CTL) are important mediators of cellular immune responses 
and play a central protective role in many human viral infections. In human 
immunodeficiency virus (HIV) infection a vigorous antiviral CTL response is induced. 
However, defining the precise role of HIV -specific CTL over the clinical course of HIV 
infection has been the subject of much speculation. Because anti-HIV CTL kill infected 
CD4+ and antigen-presenting cells, some investigators suggest that they mediate CD4+ T 
cell depletion, contributing to the immunopathology associated with progression to 
I 
AIDS. An extensive body of evidence now supports at least a partially protective role for 
HIV -specific CTL in controlling viral replication and delaying disease progression. 
However it is also clear that anti-HIV CTL fail to control HIV infection indefinitely . 
. 
Multiple diverse mechanisms with the potential for contributing to the progressive 
deterioration of HIV -specific CTL have been shown to arise over the natural course of 
HIV infection, but the relative contribution of the various mechanisms to CD8+ T cell 
dysfunction has not yet been clearly defined. 
The present study examined properties of anti-HIV CTL at various stages of disease. The 
primary objectives of the experiments were to further elucidate the biological relevance 
of HIV -specific CTL, and identify reasons for their inadequate immunoprotective role. 
The CD8+ T cell population that persists through the advanced stages of infection was 
examined, to determine if characteristics peculiar to progressive infection were imposed 
on CTL over the course of disease. HIV -specific memory T cell responses of individuals 
11 
at various stages of infection were examined longitudinally, to identify immunological 
and virological parameters affecting the maintenance of HIV -specific memory T cells, 
and to determine the relationship between the expanded CDS+CD2S- T cell population 
and disease progression. 
The studies clearly demonstrate that CDS+ T cells retain many functional and genetic 
attributes through the advanced stages of HIV infection. However, an in vivo defect in the 
ability to generate an effector CTL response becomes evident in the later stages of 
disease, despite the persistence of intact HIV -specific memory CTL precursors. This 
defect is overcome with effective therapy, allowing reconstitution of CDS+ T cell 
I 
immune responses, including HIV -specific CTL activity, even following prolonged 
periods of advanced infection. The accumulation of CDS+CD2S- HIV -specific CTL was 
found to be associated with progressive disease, and these cells showed a skewed T cell 
. 
receptor (TCR) beta chain variable gene (~V) usage and decreased cytokine output in 
comparison to their CDS+CD2S+ counterparts. Most HIV -infected individuals maintained 
stable anti-HIV memory T cells over prolonged periods of effective viral suppression, but 
a minority demonstrated a specific defect in memory T cell maintenance that was 
associated with present or past CD4+ T cell depletion. 
The results of this thesis confirm the importance of HIV -specific CTL in controlling HIV 
disease progression and identify some of the determinants related to the CDS+ T cell 
dysfunction that is observed concurrent with progression to AIDS . 
lll 
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CHAPTER! 
Cytotoxic T Lymphocytes in Human Immunodeficiency Virus Type-1 Infection: 
Important or Impotent? 
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Memorial University of Newfoundland, St. John's, Newfoundland, Canada 
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1.1 Abstract 
Virus-specific cytotoxic T lymphocytes (CTL) potentially protect against viral 
infection, or once infection has occurred, limit viral replication and prevent the 
development of associated disease. Although there is evidence that generation of anti-
HIV CTL allows a small minority of individuals to resist HIV infection, once HIV 
infection does occur, even potent CTL responses fail to control HIV replication 
sufficiently for protection from disease progression. Despite this ultimate failure, many 
investigators believe that an effective anti-HIV CTL response at least temporarily limits 
I 
HIV replication and delays disease progression. In this review, we describe the salient 
characteristics of anti-HIV CTL, discuss some of the evidence that anti-HIV CTL 
modulate viral replication and disease course and present several of the more prominent 
explanations for their eventual failure. We conclude that strategies for modulating the 
CTL response in HIV -infected individuals should be applied together with highly active 
antiretroviral therapy to maintain or elicit anti-HIV CTL responses. If such strategies 
reduce dependence on antiretroviral therapy for suppression of HIV replication, they will 
provide direct evidence that anti-HIV CTL influence the rate of HIV replication and 
disease progression. 
Key words: Cytotoxic T lymphocytes, HIV, AIDS 
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1.2 Introduction 
Through their specific lysis of infected host cells, cytotoxic T lymphocytes (CTL) 
are important mediators of protective cellular immunity. CTL are primarily CD8+ T 
lymphocytes that recognize foreign peptides presented by class I major histocompatibility 
complex (MHC) molecules [1]. When the antigen specific T cell receptor (TCR) of 
CD8+ T cells encounters antigenic peptide/MHC complexes and receives appropriate co-
stimulatory signals, the T cell becomes activated, divides and differentiates into a CTL. 
Subsequent contact with cells expressing that antigen triggers CTL-mediated killing. CTL 
normally kill their target cells either by releasing perforin, which polymerizes an
1
d forms 
pores on the target cell membrane, or by expressing fas ligand at their cell surface. Fas 
ligand triggers programmed cell death by binding the fas receptor on sensitive target cells 
[2]. 
Studies of lymphocytic choriomeningitis virus (LCMV) infection in mice first 
demonstrated the central role of CTL in viral infections and also introduced 
immunologists to their ambivalent potency [1 ,3]. LCMV is not cytopathic, therefore, it is 
quite possible for virus and host to coexist. Under certain conditions, LCMV -specific 
CTL effectively control viral replication, however, when CTL arise too late against an 
already entrenched virus, they can mediate significant, and even lethal immunopathology. 
Anti-viral CTL have subsequently been shown to play an important protective role in 
controlling many human viral infections such as influenza, cytomegalovirus (CMV) and 
Epstein-Barr virus (EBV) [4-6]. However, it has been proposed that HIV-specific CTL 
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contribute to the immunodeficiency associated with progressive HIV infection by 
eliminating HIV-infected CD4 + T cells and antigen presenting cells [7]. 
1.3 CTL Responses to HIV infection 
Infection with HIV induces a vigorous antiviral cellular immune response. HIV-
specific CTL were first described in 1987 with the direct detection of CTL specific for 
both .@g and env gene 'products in freshly-isolated peripheral blood mononuclear cells 
(PBMC) [8] . This level of CTL activity was hitherto unreported for viral infections and 
subsequently has only otherwise been described for chronic infections with human T 
lymphotropic virus type 1 (HTL V -1 ), another T lymphotropic retrovirus [9]. 
The anti-HIV CTL response is as remarkable for its diversity as for its magnitude. 
Most infected indivi~uals harbor CTL specific for multiple HIV peptide epitopes 
presented by several HLA molecules [10,11]. Anti-HIV CTL responses involving six or 
more different peptides from an assortment of HIV proteins are common and it is very 
likely that not all responses are detected [12]. At the opposite extreme, cases where the 
anti-HIV CTL response was apparently directed against only a single .@g epitope for 
several years have also been described [13]. 
Although anti-HIV CTL are predominantly directed against peptide products of 
the major .@g, pol and env genes, the regulatory protein products of the tat and nef genes 
are also targeted [ 14]. A large number of HIV CTL peptide epitopes have been identified 
and recorded in the Los Alamos HIV Molecular Immunology database [15]. No 
particular pattern of epitope distribution is apparent as epitopes cluster in some regions of 
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the viral genome and are evenly distributed through other regions. In many instances, 
multiple HLA class I molecules can present the same epitope and although individuals 
generally respond to HIV in a predictable manner based on their HLA type, there are 
numerous examples of individuals with a common class I molecule not responding to the 
same epitope [14,16-18] . These studies indicate that multiple complex factors govern the 
potentially extensive CTL response against HIV. 
1.4 Characteristics of anti-HIV CTL 
Perhaps the most notable characteristic of anti-HIV CTL is their extrem~ly high 
frequency in peripheral blood. This high CTL frequency relates to chronic HIV 
replication and the attendant stimulation of CD8+ T cells. Persistent HIV replication and 
immune activation appears to affect the phenotype of both anti-HIV CTL and an 
inordinately large proportion of bystander CD8+ T cells. The percentage of CD8+ T cells 
expressing activation markers such as CD38 and HLA-DR is significantly elevated in 
progressive HIV infection, and inversely correlated with the percentage of CD8+ T cells 
expressing CD28 [19,20]. Circulating anti-HIV CTL activity is concentrated within the 
CD38+HLA-DR+CD28- population, which decreases in size in parallel with decreased 
viral replication [20,21]. This supports the general view that CD8+CD28- T cells are 
effector cells turning over rapidly in vivo from CD28+ precursors. Loss of CD28 
expression in vitro signifies replicative senescence and the shortened telomeres of CD28-
cells circulating in HIV infection may indicate the antigen-driven accumulation of HIV-
specific CTL no longer capable of clonal expansion [22]. However, recent data showing 
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that some anti-HIV CTL memory precursor cells are CD28- and that certain CTL 
specificities may be confined to a CD28- population suggest this view of the origin of 
CD28-CD8+ T cells in HIV infection is at least partly an oversimplification [23-25]. 
Mobilization of inherently CD28-CD8+ T cells from mucosal sites of HIV replication, 
such as the gut, has also been proposed to explain the rapid and pronounced increase in 
circulating CD28-CD8+ T cells in HIV infection [26]. Intestinal intraepithelial 
lymphocytes (IEL) hav~ an extremely limited TCR repertoire, yet IEL from simian 
immunodeficiency virus (SIV)-infected macaques can mediate CTL activity against 
several SIV antigens [27-29]. Along with their specificity and oligoclonality, other 
intriguing similarities between IEL and the circulating CD28-CD8+ T cells m HIV 
infection include constitutive cytotoxicity, autoreactivity and poor proliferative potential 
[30,31]. However, there is no direct evidence that IEL migrate to the peripheral 
circulation. 
Chronic activation of anti-HIV CTL probably underlies several other phenotypic 
peculiarities that develop in progressive HIV infection. Under some conditions, receptors 
first described on natural killer (NK) cells and termed killer inhibitory receptors (KIR), 
are also expressed on T cells. Engagement of self-MHC class I molecules by these 
receptors suppresses activation of the cytotoxic cell's cytolytic machinery. For NK cells, 
this appropriately allows expression of cytotoxicity against allogeneic cells or tumor cells 
that have down-regulated expression of class I MHC molecules, while preventing the 
killing of cells expressing self MHC class I molecules. Increased expression of KIR on T 
cells in HIV -infected individuals reduces anti-HIV CTL-mediated lysis of autologous 
target cells in vitro [32,33]. There is speculation that KIR expression on chronically 
6 
activated T cells reflects an adaptive mechanism reducing immunopathology associated 
with unresolved CTL activation, but expression of these receptors could also reduce the 
efficiency of CD8+ T cell-mediated viral suppression. 
Reduced expression of components of the TCR signal transducing complex also 
compromises the effector function of T cells from HIV -infected individuals [34,35]. 
Overnight culture of peripheral blood T cells from HIV -infected individuals with 
interleukin-2 (IL-2) restores expression of the CD3 zeta chain to normal levels and 
rescues previously undetectable HIV -specific CTL activity [35]. Unfortunately, the effect 
of in vivo IL-2 administration on HIV -specific CTL activity has not yet been reported. 
f 
The mechanism behind down-regulation of components of the TCR signal transducing 
complex remains obscure, but similar findings have been reported in cancer patients with 
high tumor burdens [3 6] . 
. 
1.5 Evidence of a protective role for anti-HIV CTL 
Untreated HIV infection usually progresses to AIDS despite a vigorous CTL response. 
This raises speculation as to the precise role of CTL over the natural course of HIV 
infection and, indeed, some studies even suggest that anti-HIV CTL have no effect 
towards reducing the risk of death in HIV-infected individuals [37]. In a recent study, 
when CD8+ T cells were depleted from macaques prior to SIV infection, virus replication 
reached higher levels in primary infection [38]. Similarly, when CD8+ T cells were 
depleted from chronically-infected macaques, a rapid and marked increase in viremia 
occurred that was again suppressed coincident with the reappearance of SIV -specific 
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CD8+ T cells [38,39]. These studies provide direct evidence of a role for cell-mediated 
immune responses in limiting HIV replication. An extensive body of evidence now 
supports at least a partially protective role for anti-HIV CTL in controlling viral 
replication and delaying disease progression (Table I). 
1.5.1 Temporal changes in anti-HIV CTL activity 
Studies of CTL activity at different stages of disease provide some evidence of a 
role for HIV -specific CTL in controlling HIV replication. During primary infection, 
plasma HIV RNA rapidly rises to extremely high levels, CD4+ T cell numbers fall and 
I 
CD8+ T cell numbers increase [ 40,41]. HIV -specific CTL become detectable and plasma 
virus load falls by several orders of magnitude before neutralizing antibodies appear [ 42]. 
In two studies of CTL responses in primary infection, one of five individuals in each 
study made no detectable CTL response [43,44]. Both these individuals had consistently 
high virus loads and rapidly progressed to AIDS. Therefore, in addition to resolving the 
viremia of acute infection, early generation of an effective HIV -specific CTL response 
may dramatically influence subsequent disease course. 
One study found that generation of CTL against HIV proteins (rev and tat) involved in 
early viral replication was of particular importance in protection against rapid disease 
progression [ 45] . 
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Table I. Evidence supporting a protective role for HIV -specific CTL 
Evidence 
CD8+ T cell depletions in SIV-
infected macaques 
Temporal changes in anti-HIV CTL 
HIV -specific CTL in long-term 
non-progressors 
HIV -specific CTL in exposed 
uninfected individuals 
Correlation of HIV -specific CTL and 
markers of disease progression 
Association between HLA type and 
disease progression 
Occurrence of CTL escape mutants 
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Studies of the TCR repertoire in primary HIV infection show that the CD8+ T cell 
response is often comprised of large (up to 40% of all T cells in the peripheral blood), but 
transient oligoclonal T cell expansions [ 46]. Although this type of response has also been 
described in acute infectious mononucleosis and may occur in other acute viral infections, 
it signifies a particularly poor prognosis in HIV infection [46,47]. Thus, in addition to or 
even more so than its strength, the breadth of the early anti-HIV CTL response may be an 
important determinant of longer-term clinical outcome. 
Throughout the asymptomatic period of HIV infection, the anti-HIV CTL 
response appears stable, with HIV -specific CTL frequency estimated at up to 1% of 
circulating T cells [48,49]. This vigorous CTL response results from continuous antigenic 
stimulation by a virus constantly replicating in multiple sites [50]. As disease progresses, 
plasma virus load increases significantly and HIV -specific CTL activity appears to 
weaken [51]. In advanced HIV infection, CD8+ T cell numbers fall dramatically and 
effector CTL virtually disappear [51]. This consistent pattern of decaying HIV -specific 
CTL responses over the course of disease progression provides circumstantial evidence 
that anti-HIV CTL play a role in suppressing viral replication and delaying disease 
progressiOn. 
1.5.2 HIV-specific CTL in long-term nonprogressors 
An extraordinarily benign disease course occurs in a small proportion of HIV-
infected individuals termed long-term nonprogressors (L TNP). This heterogeneous group 
is thought to consist mostly of very slow progressors with very few true nonprogressors. 
Several studies have shown strong persistent HIV -specific CTL responses in L TNP and it 
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has been proposed that HIV -specific CTL from L TNP may have distinct features 
responsible for prolonging viral suppression and the asymptomatic phase of infection [52-
54]. The CTL responses of L TNP generally involve simultaneous recognition of multiple 
epitopes and, in some cases, target conserved HIV sequences essential for viral 
replication [12,55,56] . CTL precursor frequencies are also reportedly higher for LTNP 
than for intermediate or rapid progressors [53,57]. Since neutralizing antibody activity is 
often weak or absent in these individuals, this implicates qualitative and quantitative 
aspects of the CTL response moreso than humoral immunity in the immune system's 
contribution to long term nonprogression ofHIV infection [53,57] . 
1.5.3 Anti-HIV CTL in exposed uninfected individuals 
A small fraction of individuals exposed to HIV through sexual contact, 
intrauterine exposure, or occupational exposure resist infection. Such resistance could 
result from genetic and/or acquired factors. Several years ago, a certain degree of natural 
resistance to HIV was demonstrated to occur through inheritance of a defective form of 
the HIV co-receptor CCR-5 [58,59]. Homozygosity for a 32 base pair deletion mutation 
at the CCR-5 locus prevents expression of the gene product, virtually abolishing 
susceptibility to infection by viruses dependent upon CCR-5 as a co-receptor. However, 
the homozygous CCR-5~32 genotype accounts for only a small percentage of the 
individuals who resist HIV infection despite repeated exposure [60,61]. Other genetic 
factors have been identified that delay disease progression but have little or no effect on 
HIV transmission. These include heterozygosity for the CCR-5~32 mutation, a CCR-2 
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co-receptor mutation (CCR-2 641), and an SDFl chemokine gene variant (SDF1-3A) [62-
64]. Although these factors may contribute to long-term nonprogression in_certain cases, 
they do not appear to be responsible for the instances of apparent resistance to infection 
that have been described. 
There is now considerable evidence supporting the idea that resistance to infection 
1s acquired through induction of HIV -specific immunity. HIV -specific CD8+ CTL 
activity in the absence uf seroconversion has been demonstrated for some individuals in 
each of the exposed uninfected groups discussed above [65-68]. Furthermore, low dose 
immunization of macaques with a live SIV vaccine induces specific cell-mediated 
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immune responses without humoral immunity. Macaques immunized in this way are 
protected from challenge with normally infectious doses of virus [ 69] . These data 
demonstrate that, in some cases, initial exposure to small amounts of an AIDS-causing 
retrovirus induces cell-mediated immunity associated with protection from infection upon 
subsequent exposure to infectious doses of the virus. 
1.5.4 Relationships between anti-HIV CTL activity and surrogate markers of disease 
progression 
Many studies have addressed the association between HIV -specific CTL activity 
and disease progression. A number have reported negative correlations between HIV-
specific CTL activity and virus load [54, 70-73] and positive correlations between HIV-
specific CTL activity and CD4+ T cell counts or proliferative responses [70,71 ,73,74]. In 
two studies using TCR-specific tetramers to quantitate HLA-A2-restricted CTL against 
@g, there was a significant association between the frequency of tetramer-binding cells 
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and disease stage [7 5, 7 6]. These data suggest that stronger HIV -specific CTL responses 
confer better control of viral replication, resulting in a slower loss of CD4+ T cells and 
delayed disease progression. 
1.5.5 Associations between HLA type and rates of disease progression 
If CTL are important in controlling HIV infection, HLA class I type should be a 
key factor in determining the rate of disease progression. Selection of epitopes is 
dependent on HLA type and selection of more conserved HIV sequences as CTL epitopes 
could contribute to longer-term control of viral replication. Although more than 50 
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reports examining the contribution of HLA type towards the outcome of HIV infection 
have been published, the associations reported have generally been weak and not always 
corroborated. This is largely due to the extreme polymorphism of the HLA complex as 
there are currently more than 300 known alleles at the HLA class I A, B and C loci [77]. 
Thus, many individual alleles are relatively rare, making associations difficult to observe 
[78,79]. 
A recent study of the association between HLA type and disease progression 
within the "genetics of resistance to infection by HIV" (GRIV) cohort tries to overcome 
this limitation [80]. GRIV is a cohort of well characterized individuals representing the 
extremes of rapid progression and nonprogression. This cohort currently consists of 200 
slow progressors and 75 rapid progressors, but because the definition of slow progression 
captures ~ 1% of HIV infected individuals, this study essentially draws on a cohort of 
20,000 individuals. Previously reported associations of HLA-B27 and B57 with slow 
progression and of HLA-B35 with rapid progression to AIDS were confirmed in this 
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study [81,82]. In addition, the "GRIV" study reported that several other HLA alleles, not 
previously associated with disease progression affect progression to AIDS more strongly. 
HLA-Bl4, Cw14, and Cw8 were found to be highly protective, while HLA-A29, B22, 
and Cw16 conveyed an increased risk of rapid progression. This study confirmed an 
important role for HLA in affecting the rate of HIV disease progression, with the 
protective effect of certain HLA alleles comparable with that afforded by heterozygosity 
for the CCR-51132 mutation. 
Another recent study took a different approach to determining whether HLA type 
affects the rate of disease progression. In this report, survival and genetic association 
I 
analyses were performed on individuals enrolled in five AIDS cohorts to determine 
whether overall or specific locus heterozygosity at the HLA class I loci confers relative 
resistance to AIDS progression [83]. Maximum heterozygosity at the HLA class I-A, B, 
and C loci was associated with slower progression to AIDS and death compared to 
individuals homozygous for one or more loci. Presumably, this is because heterozygosity 
allows presentation of a broader range of HIV peptides and potentially generates a more 
diverse immune response. 
1.5.6 Viral mutants that escape CTL recognition 
The rapid rate of HIV replication combined with the high error rate of reverse 
transcriptase produces an extremely high mutation rate for HIV [84,85] . Within an HIV-
infected individual, this produces vast numbers of mutants. However, only those specific 
mutations conferring an advantage to the virus selectively accumulate [86]. Therefore, if 
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CTL are important for controlling HIV infection, it is reasonable to speculate that 
mutations in CTL epitopes that serve as a mechanism of immune escape will be selected. 
Considerable evidence has been gathered suggesting that escape from CTL recognition 
plays a role in HIV persistence [87 ,88]. CTL escape mutants emerge in primary infection 
and, in two cases, immune escape after 9-12 years of asymptomatic infection was 
associated with rapid progression to AIDS [13,89,90]. When an autologous ex-vivo 
expanded nef-specific CTL clone was adoptively transferred back into the donor, viral 
escape mutants lacking the specific sequence recognized by the CTL quickly emerged 
and the patient rapidly progressed to AIDS [91]. In this case, there is also a possibility 
f 
that the mutation in nef increased the virulence of the virus, but it nonetheless indicates 
that HIV -specific CTL can control viral replication in vivo and exert selective pressure on 
the viral quasispecies present. 
Perhaps the most definitive evidence for an association between HIV mutational 
escape of CTL recognition and disease progression comes from a recent study in the SIV 
system [92]. The specificity of anti-SIV CTL was determined in SIV -infected macaques 
early in infection and selective pressure for mutations within CTL epitope sequences was 
compared with other viral sequences. The authors observed selective accumulation of 
mutations within viral CTL epitopes in concert with loss of immunological control of 
viral replication. Mutational escape from CTL recognition is discussed in greater detail 
below. 
15 
1.6 Why anti-HIV CTL ultimately fail 
If anti-HIV CTL do delay disease progressiOn, they clearly do not mediate 
lifelong protection from progression to AIDS. A key unanswered question is how HIV 
manages to persist, replicate and eventually cause disease despite a vigorous anti-HIV 
CTL response. A number of mechanisms have been proposed to explain this apparent 
paradox, but no consensus as to the in vivo relevance of any of these mechanisms has 
emerged (Table II). 
1.6.1 Exhaustion of HIV-specific CTL 
In some cases of advanced HIV infection, neither circulating nor inducible HIV-
specific CTL activity is detectable, suggesting that the repertoire of effective anti-HIV 
CTL may have been· depleted by clonal exhaustion [51]. Clonal exhaustion of an 
antiviral CTL response was previously demonstrated in mice infected with high doses of 
a rapidly replicating strain of LCMV [93]. A similar situation may arise in HIV 
infection, where prolonged activation and expansion of HIV -specific CD8+ T cells could 
push these cells to the limit of their replicative lifespan [94,95]. The CD8+ T cells ofHIV 
infected individuals have significantly shorter telomeres than those of age-matched non-
infected controls indicating a history of extensive cell division, limited replicative reserve 
and possible proximity to clonal exhaustion [96,97]. This is particularly true for the 
CD8+CD28- T cell subset, which markedly expands following HIV infection. In primary 
infection, exhausted HIV -specific CTL clones are supplanted by new dominant clones, 
but if exhaustion were to occur at a later stage of disease, with T cell number and 
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Table II. Possible mechanisms for the ultimate failure of HIV -specific CTL 
Mechanism 
Exhaustion of HIV -specific CTL 
Apoptosis of HIV -specific CTL 
Loss of CD4+ T cell help 
Antigenic variation 
Down regulation of surface 
HLA expression 
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function more severely compromised, it might be impossible for new responses to arise 
[98]. 
1.6.2 Apoptosis of HIV-specific CTL 
Abnormally high levels of apoptosis occur m the CD4+ and CD8+ T cell 
populations of HIV -infected individuals [99] . Much of this apoptosis may be related to 
overexpression of fas and•fas ligand. Infection of CD4+ T cells or macrophages with HIV 
upregulates fas ligand expression and the proportion of CD4+ and CD8+ T cells 
expressing fas also increases in HIV infection [100-102]. This raises the possibility that 
f 
HIV -infected cells could kill HIV -specific CTL they encounter, in a manner similar to 
that proposed for the killing of tumor-specific T cells by fas ligand-expressing malignant 
cells [103]. Macaques infected with an attenuated SIV strain encoding a defective nef 
. 
protein developed strong SIV -specific CTL responses, whereas animals infected with a 
pathogenic SIV strain had low to absent SIV -specific CTL responses [ 1 04] . The 
investigators in this study then demonstrated that while infection of CD4+ T cells in vitro 
with the pathogenic strain of SIV upregu1ated fas ligand expression, the nef-defective 
strain had no such effect. Upregulation of fas ligand expression by nef in infected cells 
could favor apoptosis of CD8+ anti-HIV CTL and provide an explanation for the role of 
HIV and SIV nef in the pathogenesis of AIDS. Further support for this possibility was 
provided by Tan et al., who showed that adoptively transferred autologous in vitro 
expanded HIV -specific CTL clones were eliminated by apoptosis within hours of 
infusion [1 05]. McKinney et al. transferred HIV -specific CTL clones into HIV infected 
and uninfected human-PBL-SCID mice and showed that the HIV -specific CTL rapidly 
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disappeared in infected recipients, while they persisted at high levels in the uninfected 
mice [106] . These studies support the possibility that increased apoptosis of HIV-
specific CTL contributes to the decline in CTL activity observed in late stage HIV 
infection. 
1.6.3 Loss ofCD4+ T cell help 
Although disappearance of CTL may account for some cases of disease 
progression, vigorous and sometimes diverse anti-HIV memory CTL activity can be 
sustained even in individuals with full-blown AIDS [51 ,107,108]. In these cases, 
circulating CTL responses are usually undetectable, while anti-HIV CTL activity temains 
inducible in vitro. Therefore, an in vivo defect in the activation of anti-HIV CTL 
memory cells appears to render these cells ineffective in advanced HIV infection. 
In our view, it is most probable that loss of CTL activity at this stage is secondary 
to the absolute loss of CD4+ T cells and impaired function of those remaining. It has 
been reported that even relatively early in HIV infection, HIV -specific CD4+ T cell 
proliferation becomes undetectable in most infected individuals [109,110]. Recently, 
however, flow cytometry-based_methods to detect intracellular cytokine (y-interferon) 
production have shown that HIV -specific CD4+ T cells persist in all individuals with 
nonprogressive infection and in most subjects with active, progressive infection [111]. 
Therefore, although proliferative responses to HIV appear to be lost at an early stage of 
infection, functional HIV -specific CD4 + cells that secrete y-interferon following 
stimulation with HIV antigens do persist into the chronic phase of infection. It is still 
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unclear how this disjunction of proliferation and cytokine production relates to HIV-
specific helper T cell function in vivo. Although the CD8+ T cell-mediated rejection of 
genetically modified HIV -specific CTL clones by HIV infected individuals with low CD4 
counts indicates the preserved ability to generate CTL responses in advanced HIV 
infection, long-term maintenance of these CTL responses is another question [112]. 
Depletion of CD4+ T cells by antibody treatment did not impair the primary CTL 
response to LCMV in mice, but the mice failed to maintain CTL memory during 
persistent infection [ 113]. If maintenance of CTL memory depends on CD4 + T cell help, 
declining CTL activity in progressive HIV infection appears inevitable in the wake of 
severe CD4+ T cell depletion. 
1.6.4 Effects of antigenic variation 
The several well-documented examples of HIV mutational escape from CTL 
discussed above share two important features [13,89-91]. In each case, there was a 
dominant CTL response to a single epitope, and the mutation, which was selected to 
fixation, disrupted binding of the peptide to the presenting HLA molecule. Restriction of 
the CTL response to a single epitope in these individuals made escape relatively easy, as 
a single mutation allowed complete evasion of the CTL response. However, as previously 
described, most HIV -infected individuals mount polyclonal CTL responses involving 
recognition of multiple HIV epitopes [10,11]. In a related model, the murine CTL 
response to a single hepatitis B virus (HBV) epitope was analyzed [114]. Diverse 
polyclonal responses were generated and no single mutation in this epitope ever affected 
all the responding T cell clones. Therefore, in most cases, mutational inactivation of a 
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single epitope is highly unlikely to be sufficient for viral evasion of the immune system. 
Simultaneous complementary mutations would be required and, until recently, 
simultaneous complementary mutations at more than two epitope sites was considered 
rare [85]. A recent study by Evans demonstrated that, in SIV -infected macaques with up 
to five concomitant CTL responses, viral mutation and immune selection produced 
dominant viral quasispecies harboring mutations within all five epitope sites [92]. This 
selection was associated with increased levels of viral replication and disease 
progression. Therefore, mutational escape from CTL recognition during HIV infection 
may be more widespread than previously anticipated. 
I Antigenic variation can affect the efficiency of the CTL response even without 
producing complete mutational escape from CTL recognition. At any one time within an 
infected individual, swarms of related but genetically distinct viruses exist as proviruses 
and virions. In many patients with concurrent CTL responses to multiple epitopes, 
mutations that would affect the CTL response exist within proviral quasispecies 
[115,116]. In an HIV-infected individual with CTL responses to two epitopes in ill!£;, the 
CTL response was unstable over time as it switched back and forth between epitopes 
[ 117]. There were concurrent fluctuations in the predominant virus sequence present, 
with escape variants for each epitope increasing in frequency when the corresponding 
CTL response was strong and decreasing as it weakened. Another study of four 
asymptomatic individuals showed that particular variants dominated the viral 
quasispecies for only short periods of time and were eliminated by HIV -specific CTL 
[118]. Thus, the CTL response and viral variants existing at any one time in an HIV-
infected person may reflect an extended series of past escapes and selections. 
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Mutations within CTL epitopes that don't affect binding to HLA molecules 
nonetheless have the potential to subvert CTL recognition. In such cases, a so-called 
altered peptide ligand (APL) is presented to the T cell, which can profoundly affect T cell 
recognition and subsequent activation of CTL effector functions [reviewed in 119]. APL 
may act simply as escape mutants which, although potentially immunogenic, are not 
recognized by the CTL response existing in the peripheral blood of an individual at a 
given time [120,121]. Alternatively, APL may actually antagonize the existing CTL 
response. In this case the APL has a partially productive interaction with the TCR, which 
through a poorly understood intracellular signaling mechanism, prevents the CTL from 
lysing even those cells infected with wild-type virus [116,122,123]. Partially recognized 
APL can also favor the virus by continuing to stimulate the expansion of CTL no longer 
effective at controlling viral replication. In the LCMV model, partial reactivity of variant 
peptides with pre-existing CTL inhibits the recruitment of CTL that can more efficiently 
recognize the variant [124]. These dual potential actions of APL to perpetuate an 
ineffective CTL response and functionally silence reactive CTL may give the virus a very 
significant survival advantage. 
1.6.5 Down-regulation of HLA class I molecules 
Downregulation of HLA expressiOn on infected cells is a common potential 
means of viral escape from CTL. Several earlier studies showed that HIV could decrease 
surface expression of HLA molecules on infected cells without examining the impact of 
this downregulation on recognition by HIV -specific CTL [ 125, 126]. Previously, HIV tat 
and/or vpu were thought to mediate this effect, but more recently, nef was found to 
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induce endocytosis of HLA class I molecules [127-129]. A separate study showed that 
target cells infected with a nef-deleted HIV mutant did not alter HLA expression and 
were fully susceptible to CTL mediated lysis, whereas cells infected with wild-type HIV 
were relatively resistant to lysis and showed up to 20-fold downregulation of HLA class I 
expression [130] . 
The significance of these findings for the ability of HIV -specific CTL to control 
viral replication in vivo is unclear. This avoidance mechanism must be incomplete 
because very strong CTL responses are induced and persist in nearly all infected 
individuals. However, with the high levels of HIV replication that occur, any reduction 
in the efficiency with which CTL recognize infected cells could have a substantia! overall 
effect on virus production and the rate of disease progression. 
1.7 Anti-HIV CTL in the era of highly active antiretroviral therapy (HAART) 
Triple combination antiretroviral drug regimens have dramatically reduced the 
incidence of HN -related morbidity and mortality [ 131]. Even in advanced HIV 
infection, HAART can effectively suppress HIV replication and increase circulating T 
cell numbers [132,133]. However, clinical reports of severe opportunistic infections, 
despite satisfactory responses to antiretroviral treatment, suggest that increased T cell 
counts may not always signify functional augmentation of the immune system [134]. 
Previous studies demonstrated HAART-related improvements in CD4+ T cell function as 
indicated by increased lymphoproliferative responses to mitogens and recall antigens, but 
HN-specific CD4+ T cell responses did not improve in the same individuals [133,135]. 
Therefore, despite overall improvements in CD4+ T cell function with HAART, it doesn' t 
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seem that HIV -specific CD4+ responses are reconstituted. However, if individuals are 
treated early enough with HAART, there is some evidence that CD4+ T cell responses to 
HIV are preserved and that this favors stronger HIV -specific CTL responses over the 
longer term [110]. 
Studies using peptide/MHC tetrameric complexes to enumerate the frequency of 
HIV peptide-specific CDS+ T cells in individuals treated with HAART have shown that 
anti-HIV CTL decline in number with effective suppression of viral replication [136-
13S]. In all cases, the frequency oftetramer-binding cells declined in patients responding 
to therapy. Most studies also show that the functional activation of anti-HIV CTL 
declines with potent suppression of viral turnover [136,137,139]. In a detailed 
longitudinal evaluation of two individuals before and after the start of combination 
therapy, both subjects had in vivo activated and memory CTL against multiple HIV gene 
products before starting therapy [136]. Effective therapy reduced the levels of in vivo 
activated HIV -specific CTL, but concurrently increased the frequency of HIV -specific 
memory CTL. Prolonged suppression of viral replication also reduced levels of memory 
CTL. Over the course of study, both subjects had transient increases in viral load 
associated with increased levels of virus-specific CTL, suggesting the immune system 
can still respond rapidly when memory CTL fall to low levels. In two other reports, anti-
HIV CTL activity was unchanged by antiretroviral therapy [140,141]. In our laboratory, 
we saw reconstitution of circulating CTL activity and inducible HIV -specific CTL 
activity in two out of three subjects with advanced HIV infection who responded to 
HAAR T with viral suppression and increased T cell counts [unpublished data]. This 
demonstrates that if antiretroviral therapy is effective, even the residual CDS+ T cell 
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population persisting through advanced HIV infection can reconstitute functional HIV-
specific CTL responses. 
Studies examining changes in the phenotype of CD8+ T lymphocytes in response 
to HAART report reduced numbers of activated CD8+ T cells (CD38+DR+CD28-), 
consistent with declining CTL activity [136,140,142]. However, the percentage of 
activated CD8+ T cells in these individuals remained significantly elevated compared 
with uninfected controls; suggesting either ongoing occult HIV replication or some other 
form of chronic stimulation of CD8+ T cells [ 142]. 
In conclusion, HAART reduces the number of activated CD8+ T cells and HIV-
, 
specific CTL activity. Since the nature of the immune system is to respond to invading 
pathogens, it is not surprising that as the antigenic burden is reduced by HAART, HIV-
specific CTL responses wane. The observations of rapid CTL responses when virus load 
. 
increases, as well as reconstitution of HIV -specific CTL responses when T cell numbers 
increase, indicate that the CD8+ T cell population largely remains intact throughout 
progressive HIV infection. The recent demonstration of continuous thymic T cell 
production throughout adult life and of increased thymic output in HIV -infected 
individuals effectively treated with HAART also supports the possibility of reconstituting 
effective CTL responses [143]. However, because the frequency of HIV-specific CTL 
rapidly declines with effective treatment, therapeutic vaccination as an alternative to 
treatment interruptions should be considered to strengthen the HIV -specific CTL 
responses of individuals being successfully treated with HAART. If such an approach 
reduces dependence on antiretroviral drugs for suppression of HIV replication below 
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detectable levels, this will clearly establish a contribution from anti-HIV CTL to 
protection from disease progression. 
1.8 Summary 
The basic question of whether HIV -specific CTL are protective or not remains 
unanswered. There is circumstantial evidence that some exposed uninfected individuals 
generate HIV -specific CTL responses that protect them from infection. Evidence of 
selective pressure exerted on HIV quasispecies by anti-HIV CTL demonstrates that the 
CTL response can impact on viral replication in vivo. Associations between particular 
HLA class I alleles and rates of disease progression strongly suggest that HLA class !-
restricted T cell responses influence viral replication. The decay of anti-HIV CTL 
activity in parallel with disease progression is also consistent with a role in delaying 
disease progressiOn. HIV -specific CTL responses appear variable in their ability to 
control HIV replication and qualitative differences in CTL responses are probably 
responsible for this. Restricted CTL responses against HIV appear particularly 
ineffective for the long-term control of viral replication, but in some individuals, even 
strong diverse anti-HIV CTL responses do little to limit viral replication. Extensive 
studies of the timing, epitope specificity and phenotype of anti-HIV CTL are required, 
together with relevant clinical follow-up to establish what CTL characteristics favor 
effective long-term suppression of viral replication. 
This review also discussed potential mechanisms for the failure of CTL responses 
m progressive HIV infection. Multiple mechanisms are speculatively implicated in 
contributing to the loss of CTL activity in advanced infection, but there is no consensus 
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as to which mechanism, if any, predominates. Both accelerated apoptosis and clonal 
exhaustion may drive absolute depletion of HIV -specific CD8+ T cells, while generation 
of escape mutants and APL reduces the functional efficiency of those remaining. 
Productive recognition of target cells by CD8+ anti-HIV CTL may also be impaired by 
reduced expression of HLA class I antigens and up-regulation of fas ligand on HIV-
infected cells. Chronic activation of CD8+ T cells subsequent to their failure to eliminate 
HIV probably produces secondary functional deficits reflected in loss of CD28 
expression, down-regulation of TCR signaling components and expression of KIR. The 
possibility of reshaping anti-HIV CTL responses with therapeutic vaccines while HIV is 
f 
suppressed by HAART may allow definition and demonstration of protective CTL 
responses against HIV. 
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1.9 Thesis Proposal and Specific Research Objectives 
When this thesis project was first proposed, the role ofHIV-specific CTL in the 
pathogenesis of HIV infection was highly equivocal. Although the majority of studies 
supported the concept that anti-HIV CTL contributed to controlling viral replication and 
delaying the onset of disease, several other observations suggested that HIV -specific CTL 
were deleterious to the infected host, mediating CD4+ T cell depletion and progression to 
AIDS. Since then, a central antiviral role for CDS+ T cells in SIV infection has been 
clearly demonstrated, and it is now widely accepted that HIV -specific CTL play a similar 
I 
protective role in HIV infection. However, it is also clear that anti-HIV CTL p er se do 
not mediate lifelong protection from progression to AIDS. Current data strongly points 
to multiple mechanisms contributing to the failure of anti-HIV CTL to control HIV 
infection indefinitely. HIV -specific CTL appear variable in their ability to slow the rate 
of disease progression, but the exact determinants involved have not yet been revealed. 
The primary purpose of this thesis was to further elucidate the biological relevance of 
anti-HIV CTL, by characterizing the CDS+ T cell response during different clinical stages 
ofHIV disease. Understanding CDS+ T cell regulation is critical for understanding 
immune pathogenesis and for developing strategies for immune intervention for HIV and 
other diseases. 
The specific research objectives of this thesis were: 
(i) to investigate the functional and genetic characteristics of the CDS+ T cell 
population in individuals with advanced HIV infection. 
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(ii) to determine the potential for reconstitution of CD8+ T cell immunity in 
individuals with advanced HIV infection. 
(iii) to examine whether the expanded CD8+CD28- T cell population from 
individuals at various stages ofHIV infection contributes to disease 
progressiOn 
(iv) to identify virological and immunological parameters affecting the 
maintenance of HIV -specific memory T cell responses over prolonged periods 
of HIV infection. 
To achieve these objectives two major studies were performed. The first involved a 
detailed examination of the CD8+ T cell population persisting through the advanced 
stages of HIV infection. It was hypothesized that, by defining CTL characteristics 
peculiar to advanced infection, where cumulative defects have been imposed on the CD8+ 
T cell population, reasons underlying the ultimate failure of anti-HIV CTL responses 
might be revealed. During this study several individuals responded to antiretroviral 
therapy, evidenced by control of viral replication to undetectable levels and partial 
reconstitution ofT cell lymphopenia. These subjects were examined for an extended 
period, to determine whether intractable defects precluded HIV -specific immune 
responses at this stage, or if, even following advanced infection, immune reconstitution 
enabled specific immune responses against HIV. 
The second study involved a larger group ofHIV-infected individuals, who were at 
various stages of infection. This group was studied to determine whether the expanded 
CD8+CD28- T cell population arising during HIV infection reflects the CD8+ T cell 
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dysfunction that occurs with disease progression, and to identify phenotypic 
characteristics that could predict persistence or degeneration of anti-HIV CTL. 
This thesis is presented in manuscript format, with each chapter representing a ' stand 
alone' research paper. The following four chapters consecutively describe the 
experimental procedures and results related to the specific objectives outlined above. The 
final chapter represents an integrated discussion on the thesis as a whole. 
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CHAPTER 2 
Functional and Genetic Integrity of the CDS+ T Cell Repertoire in Advanced HIV 
Infection1 
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2.1 Abstract 
Background: HIV-specific cytotoxic T lymphocyes (CTL) can restrict HIV replication 
in acute and chronic infection, but disease progression occurs in parallel with declining 
CTL activity. Understanding why CTL fail to control HIV replication might reveal 
important mechanisms of disease progression and enhance prospects for developing 
effective CTL-based immunotherapies. 
Objectives: To investigate ,the functional integrity, T cell repertoire diversity, and HIV 
reactivity of CD8+ T lymphocytes in individuals with advanced HIV infection. 
Methods: Individuals were considered to have progressed to advanced HIV infection if 
I 
their total T cell count was <500/fll blood on at least two successive clinic visits. CD8+ T 
cells from these individuals were analyzed for CTL function, HIV reactivity and T cell 
receptor (TCR) diversity by chromium release assays and reverse transcriptase 
polymerase chain reaction (RT-PCR). 
Results: CD8+ T cells from all individuals with advanced HIV infection proliferated and 
differentiated into functional CTL in vitro. Despite extremely low T cell counts and 
previous AIDS defining illnesses, 6 individuals had inducible anti-HIV CTL responses. 
In two additional cases, HIV -specific CTL activity became detectable following 
significant treatment-associated remission ofT cell lymphopenia. Assessment of TCR~V 
gene family representation and ~V gene intrafamily diversity indicated CD8+ T cell 
repertoire diversity is maintained through advanced HIV infection. 
Conclusions: These data suggest that HIV -specific CTL activity can be selectively 
compromised while the functional and genetic integrity of the CD8+ population as a 
whole remains intact. A substantial fraction of individuals retain inducible anti-HIV CTL 
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activity through advanced HIV infection and, in at least some cases, effective treatment 
can restore HIV -specific CTL responses even at this late stage of disease. 
Keywords: Human immunodeficiency virus (HIV), cytotoxic T lymphocytes (CTL), T 
cell receptor (TCR) repertoire. 
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2.2 Introduction 
There is considerable evidence that CTL-mediated control of HIV replication delays 
disease progression. HIV -specific CTL arise during primary HIV infection and typically 
persist throughout the clinically asymptomatic period [1, 2]. The appearance of HIV-
specific CTL coincides with decreasing viremia, and anti-HIV CTL inhibit viral 
replication and eliminate virus-infected cells in vitro [3-8]. Strong HIV -specific CTL 
responses occur in long-term non-progressors and in a significant fraction of HIV-
exposed uninfected individuals [9-12]. Anti-HIV CTL diversity in primary infection 
predicts slow disease progression and emergence of CTL-escape mutants sometimes 
f 
precedes rapid progression to AIDS [1, 13-15]. 
Untreated HIV infection ordinarily progresses to AIDS, despite vigorous CTL responses. 
Over the transition to advanced infection, HIV -specific CTL activity weakens as total 
CD8+ T cell numbers fall [16-18]. Persistence of anti-Epstein-Barr virus (EBV) CTL and 
general CTL activity, while anti-HIV CTL disappear, suggests selective loss of HIV-
specific CTL [16, 19, 20]. Signs of cellular senescence such as proliferation defects and 
short telomeres occur in CD8+ T cells from HIV -infected individuals, particularly within 
the disproportionately expanded CD28- subset [21 , 22]. At least two non-exclusive 
theories address CTL decline in HIV infection: (1) depletion through clonal exhaustion or 
apoptosis [23-27]; and (2) anergy imposed through inadequate T cell help or 
inappropriate antigen presentation [28-31] . Defining CTL characteristics peculiar to 
advanced infection may reveal the relevance of these and other mechanisms to CTL 
failure. This information is important for understanding disease progression and 
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evaluating prospects for CTL-based immunotherapy and reconstitution of CD8+ T cell 
immunity. 
It is presently uncertain whether HIV -specific precursors, or even normal functional 
attributes of CD8+ T cells, persist through advanced infection [32]. While primary 
infection is associated with oligoclonal expansions within TCR ~ chain variable gene 
(TCR~V) families, the status of TCR repertoire diversity throughout chronic infection is 
unclear [13, 33, 34]. More research is needed to determine whether CD8+ T cells in 
advanced HIV infection comprise a functionally and genetically intact population with 
residual immune potential against HIV and other pathogens. 
We examined CD8+ T cells from 13 individuals with advanced HIV infection, for 
proliferative potential, CTL function, HIV reactivity and TCR diversity. Although we 
rarely detected circulating CTL, CDS+ T cells from all 13 individuals proliferated and 
differentiated into functional CTL in vitro. Anti-HIV CTL were initially detected in 6/1 2 
individuals, but they became detectable following treatment-associated remission of T 
cell lymphopenia in 2 additional cases. While CD8+ T cells in the circulation and 
following in vitro stimulation were predominantly CD28+, the anti-HIV CTL we detected 
in this group were predominantly CD8+CD28-. Relative TCR~V gene family expression 
levels and intrafamily diversity largely mirrored the range exhibited by uninfected 
controls. These results suggest that over the course of HIV infection, HIV -specific CTL 
activity deteriorates while the functional and genetic integrity of the CD8+ population 
generally remains intact. 
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2.3 Methods 
2.3.1 Study subjects 
HIV-infected individuals were recruited through the Infectious Disease Clinic of the St. 
John's General Hospital, St. John's, NF, Canada. Individuals presenting with total T cell 
counts <500/1-ll peripheral blood on at least two consecutive clinic visits were considered 
to have progressed to advanced HIV infection and recruited for this study. At each visit, 
clinical evaluation was performed and blood was drawn for measurement of plasma HIV 
RNA using Amplicor HIV-1 Monitor™ quantitation kits (Roche Diagnostic Systems 
I 
Inc., Mississauga, ON), for measurement of peripheral blood lymphocyte (PBL) subsets 
and for our research study. Ethical approval was obtained from the Memorial University 
Faculty of Medicine Human Investigation Committee and informed consent for drawing 
blood samples and accessing medical records was obtained from all participants. 
Uninfected controls were laboratory or hospital personnel. 
2.3.2 Sample preparation 
Heparinized whole blood samples were processed within 4 hours of collection. Samples 
were centrifuged at 500g for 10 minutes and plasma was removed and immediately 
frozen at -70 °C. Packed blood was diluted to twice the original volume with sterile 
phosphate buffered saline (PBS), transferred to 50 ml centrifuge tubes and underlaid with 
an approximately equal volume of Ficoll-paque lymphocyte separation medium 
(Pharmacia Chemicals, Dorval, Quebec). After centrifuging for 30 minutes at 400g, the 
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peripheral blood mononuclear cell (PBMC) layer was collected, washed twice in PBS 
with 1% fetal bovine serum (FBS; Gibco, Grand Island, NY), resuspended in lymphocyte 
medium (RPMI 1640 with 10% FBS, 10 mM Hepes, 2 mM L-glutamine, 1% 
penicillin/streptomycin, and 2x10-5 M 2-mercaptoethanol; all from Gibco) and counted. 
Freshly-isolated cells were used for HLA typing, B lymphoblastoid cell line (BLCL) 
generation, determining circulating CTL activity and determining the proportion of CD8+ 
T cells expressing CD2&. A portion of the freshly-isolated cells were stimulated in vitro 
prior to determining anti-HIV CTL activity and TCR repertoire status. Class I human 
histocompatibility-linked antigen (HLA)-A and B antigens were determined using 
standard serologic techniques [35]. BLCL were generated by infecting 5x1061 PBMC 
with 2.5 ml supernatant from the B95-8 cell line obtained from the American Type 
Culture Collection, (ATCC CRL1612, Rockville, MD). After 24 hours, cells were 
pelleted and resuspended in lymphocyte medium containing 20% FCS and 1 11g/ml 
cyclosporin A. Transformation usually occurred after 2-3 weeks, and cell lines were 
preserved in liquid nitrogen. 
2.3.3 Lymphocyte stimulation 
Approximately 1x107 freshly-isolated PBMC were stimulated by an autologous mixed 
lymphocyte reaction (AMLR), similar to that previously described [36]. Briefly, 90% of 
the cells (responders) were cultured in plain lymphocyte medium, with the remaining 
10% (stimulators) cultured in lymphocyte medium supplemented with 5 11g/ml purified 
phytohemagglutinin (PHA-P; Wellmark Diagnostics, Guelph, ON) and 10 U/ml 
recombinant human interleukin-2 (IL-2; Hoffmann La Roche, Nutley, NJ). After 3 days, 
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the stimulators were washed twice with lymphocyte medium and added to the responder 
population. Three days later, 5 U/ml IL-2 was added, and culture continued for an 
additional 7 days, with addition of lymphocyte medium supplemented with 5 U/ml IL-2 
as required. 
2.3.4 Flow cytometry 
To determine the proportion of CDS+ T cells expressing CD28, cells were washed once in 
PBS containing 5 mM EDTA and 0.1% bovine serum albumin (BSA; Sigma Chemical 
Co., St. Louis, MO) and incubated for 20 minutes at 4 °C with fluorescein isothiocyanate 
I (FITC)-conjugated anti-CD3 (Dako Diagnostics, Mississauga, ON), phycoerythrin (PE)-
conjugated anti-CD28 (Becton Dickinson, Mississauga, ON) and Peridinin Chlorophyll 
Protein (PerCP)-conjugated anti-CD8 (Becton Dickinson). Samples were washed once 
after staining, resuspended in 0.5% paraformaldehyde in PBS and analyzed on a 
F ACStarPius analyzer (Becton Dickinson) after excitation at 488 nm with an argon laser. 
2.3.5 Lymphocyte separations 
To remove CD28+ cells before cytotoxicity assays, cells were pelleted, washed in PBS 
with 5 mM EDTA and 0.1% BSA and incubated for 20 minutes at 4 °C with 5 llg/106 
cells of purified anti-CD28 (Becton Dickinson). Cells were washed once more and then 
incubated at 3x106/ml in PBS with 5 mM EDTA and 0.1% BSA at 4 °C for 45 minutes on 
a rotating mixer with goat-anti-mouse IgG coated magnetic beads (Dynal Inc., Great 
Neck, NY) at a 10:1 bead-to-target cell ratio. Bound cells were separated by holding the 
tube against a magnet, removing the supernatant, washing the beads gently in PBS and 
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repeating the process. For depletion studies the unbound cells were centrifuged and 
resuspended based on starting cell numbers for use as effectors in cytotoxicity assays. 
For enrichment studies, the unbound cells were counted and effector:target (E:T) ratios 
re-established with purified cells. Flow cytometry revealed that this depletion method 
removed >98% of CD28+ cells (data not shown). 
For TCR repertoire analysis CD8+ T cells were isolated from the stimulated cultures. 
Cells were pelleted, washed, and incubated at 3x106/ml in PBS with 5 mM EDTA and 
0.1% BSA at 4 °C for 45 minutes on a rotating mixer with anti-CD8 coated magnetic 
beads (Dynal Inc.) at a 10:1 bead-to-target cell ratio. Bound cells were separated as 
described above and frozen at -70 °C for RNA extraction. 
2.3.6 Cytotoxicity assays 
Total CTL activity was assessed in an anti-CD3 redirected killing assay using the P815 
murine mastocytoma cell line (ATCC TIB-64). Freshly-isolated PBMC, at E:T ratios of 
50:1, 25:1, and 12.5:1, were used to assess circulating total CTL activity. AMLR-
stimulated effector cells were tested for total CTL activity at ratios of 20: 1, 1 0: 1, and 5: 1. 
P815 cells (1x106) were labeled for 90 minutes with 100 ).!Ci Na/1Cr04 (Amersham Life 
Sciences, Arlington, IL), washed four times with PBS containing 1% FBS, counted, and 
resuspended at lx105/ml. Effector and target cells were incubated in duplicate in 96-well 
culture plates at a final volume of 300 ~-tl/well. The anti-CD3 mAb OKT3 (ATCC 
CRL8001 ) was added to a final concentration of 1 ).!g/ml at the time of the assay. 
Control wells contained effector and target cells in the absence of anti-CD3. Minimum 
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and maximum release wells contained target cells in medium or 1N HCl respectively. 
After 5 hours incubation, 100 f.!l cell-free supernatant was removed and then counted in a 
Wallac 1480 gamma counter. Percent killing was determined by the formula: 
(Test 51 Cr release - spontaneous release) x 1 00 I maximum 51 Cr release - spontaneous 
release. 
Spontaneous release was less than 25% in all assays. Results were considered positive 
when the percent specific 51 Cr release in the test wells was at least 10% above that of the 
control wells. 
HIV-specific CTL activity was assessed usmg autologous or HLA-matched BLCL 
I 
infected with the following recombinant vaccinia viruses: vVK1 (gag/pol), vDK1 (gag), 
vCF21 (pol), vPE16 (gp160), vTFnef(nej), and vSC8 (E. Coli 0-galactosidase, control) 
(all from the NIH AIDS Research and Reference Reagent Program, Rockville, 
Maryland). 1x106 BLCL were infected with 15 plaque forming units (pfu)/cell overnight 
and labeled with 51 Cr as described above. In most cases E:T ratios were 50:1, 25:1 , and 
12.5:1. The assay was performed as described above, except the anti-CD3 antibody 
OKT3 was added to a concentration of 5 f.!g/ml to duplicate wells containing the high E:T 
ratio to confirm the role of the TCR in target cell killing. In all cases where HIV -specific 
CTL activity was reported, lysis was inhibited by OKT3. 
2.3. 7 T cell repertoire analysis 
TCR 0 chain V gene family expression levels were assessed as in [3 7] with slight 
modifications. Briefly, RNA was extracted from bead bound CD8+ T cells using Trizol 
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(Gibco BRL, Burlington, ON) and eDNA was synthesized with a first strand eDNA kit 
(Pharmacia Biotech Inc., Baie d'Urfe, Quebec). The equivalent of 1 ~g RNA was split 
into 24 polymerase chain reaction (PCR) mixtures, each incorporating 1 of 24 TCR~V 
gene family-specific primers, a common C~ primer and a pair of Ca primers for an 
internal positive control [primers as in 37]. Reactions were run in 20 ~1 volumes for 30 
cycles under standard conditions, and products separated on 2% agarose gels. Digital 
image analysis, with "Alphaease" software, was used to express ~V band intensities as a 
fraction of the internal control Ca band intensity to compare relative expression levels of 
individual ~V families between samples. TCR~V gene intrafamily junctional length 
I 
diversity was assessed by separating PCR products on 6% sequencing gels and 
visualizing individual bands (spectratypes) by silver staining. This yields 6-9 bands per 
family each differing from the next by 3 base pairs in length [38]. 
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2.4 Results 
2.4.1 Subject characteristics 
General immunological characteristics of the 13 subjects included in this study together 
with their HIV virus load measurements at time of study entry are listed in table 1. All 
subjects had total T cell counts <500/J.Ll on at least two occasions prior to their inclusion 
in the study. Over the following 12 months, T cell numbers remained relatively stable for 
all subjects except 028, 069, and 083. These individuals had substantial increases in their 
T cell numbers and all 3 had T cell counts well above 500/J.!l 12 months from entry into 
I 
the study. Virus load measurements also remained relatively stable for all subjects except 
083, who had steadily decreasing plasma virus levels over this same period. Increasing 
CDS+ T cell counts in subjects 028 and 069 were associated with sustained suppression of 
. 
plasma virus load at undetectable ( <400 copies HIV RNA/ml) levels. All of the 13 
individuals included in this study received triple combination antiretroviral therapy 
consisting of either 2 nucleoside analogue reverse transcriptase (RT) inhibitors (NRTis) 
with a protease inhibitor (PI), 1 non-nucleoside analogue RT inhibitor (NNRTI) and 1 
NRTI with a protease inhibitor or 1 NRTI with 2 Pis. Sustained responses in terms of 
virus load suppression or remission of lymphopenia did not occur in any of the other 10 
individuals despite their receiving equally potent antiretroviral therapy. Subject 029 
discontinued all antiretroviral therapy when no substantial reduction in plasma virus load 
was achieved. No clinical symptoms of opportunistic infections were apparent at times 
of immunologic testing for any of the individuals. 
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Table 1. Subjects' Immunologic Characteristics and HIV Plasma Virus Load at Study 
Entry 
Subject T cells/ CD4+ CD8+ %of Log10 HIV tens+ tPercent redirected 
ID !J.l blood T cells/ T cells/ CD8+ RNA T cell lysis ofP815 cells 
!J.l blood !J.l blood T cells ( copies/ml) Expansion 
CD28+ in vitro 
Circulating Cultured 
effectors effectors 
004 264 8 232 82 5.69 8x 4 36 
*oo5 271 10 230 47 5.1 3x 10 40 
*oo9 203 36 143 65 5.86 3x 1 32 
*o23 312 21 256 62 5.31 6x 3 28 
·o2s 176 3 141 86 4.48 5x 37 57 
*029 442 42 409 57 5.21 5x 7 29 
*o38 231 0 148 65 5.85 5x 10 40 
56 204 20 164 44 5.13 2x 5 90 
60 176 0 136 70 4.8 6x §ND 71 
*o69 444 52 348 30 2.85 3x 7 63 
. 
79 333 64 243 68 2.6 4x 1 34 
83 325 84 218 47 5.88 9x 6 65 
*o91 465 46 328 57 5.88 2x ND 46 
* Subjects with previous AIDS-defining illnesses. 
t Approximate in vitro expansion over 1 0 days of stimulation, based on total starting and 
final CD8+ T cell numbers derived from flow cytometry records and cell counts. 
t Refers to percent anti-CD3 redirected lysis of P815 cells at high E:T ratios; 50:1 for 
freshly-isolated cells and 20:1 for in vitro stimulated cells. 
§ ND = not done. 
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2.4.2 Proliferative and differentiation potential of CDS+ T cells in advanced HIV 
infection 
The proliferative potential of CD8+ T cells was assessed directly, from the level of 
expansion following stimulation, and indirectly, from the proportion of CD28+ cells in 
the CD8+ T cell population. Results are shown in Table 1. CD8+ T cells from all 13 
subjects proliferated in vitro, with expansion levels ranging from 2x to 9x. This shows 
that at least some of the CD8+ T cells remaining at this advanced stage of infection can 
still replicate when appropriately stimulated. CD28+ cells accounted for the majority of 
' 
circulating and cultured CD8+ T cells in 9 of 13 subjects (table 1 and fig. 1). This is in 
contrast to a control group of subjects at an earlier stage of infection, matched for viral 
load measurements but having total circulating T cell counts above 1 000/f.ll , where none 
had >50% CD28+ CD8+ T cells, x2 with Yates correction= 10.82; p< .005. In this control 
group, the percentage of circulating CD8+ T cells expressing CD28 ranged from 20% to 
45% (mean± SD = 35 ± 7%). We selected this control group ofHIV-infected individuals 
at an earlier stage of infection for comparison of circulating total CTL and inducible anti-
HIV CTL, as well as to illustrate effects specific to advanced HIV as opposed to HIV 
infection per se. Matching for virus load was done to demonstrate that immunological 
differences did not merely reflect the high circulating plasma virus load common in 
advanced HIV infection. 
Total CTL activity was tested by anti-CD3 redirected lysis ofP815 cells. Of 11 subjects 
tested for total circulating CTL, only one was initially positive (table 1 ). For 2 
individuals who initially tested negative, circulating CTL activity became detectable 
following significant increases in their T cell counts. In contrast, in the control group 
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matched for plasma virus load but with > 1000 total T cells/ f-Ll peripheral blood, 13/ 13 had 
circulating CTL activity, x2 with Yates correction = 16.65; p< .001. Total circulating 
CTL activity at an E:T ratio of 50:1 ranged from 14% to 60% (mean± SD = 33 ± 14% ) 
in the control group. This same assay was performed following in vitro stimulation, to 
determine the capacity of the CD8+ T cells to differentiate into functional CTL. All 
subjects in both the advanced-stage group and the control group had demonstrable total 
CTL activity following in vitro stimulation, indicating that functional CTL precursor cells 
were present in all cases (table 1 ). At an E:T ratio of 20:1 , total stimulated CTL activity 
in the control group ranged from 31% to 87% (mean± SD = 65 ± 15%). These results 
demonstrate that the CD8+ T cell population persisting in advanced HIV infection is 
mostly CD28+ and includes T cells with the capacity to proliferate and differentiate into 
functional CTL. How~ver, circulating CTL activity appears dependent upon a minimal 
circulating total T cell number and is usually undetectable in advanced HIV infection. 
2.4.3 HIV -specific CTL 
Anti-HIV CTL activity after stimulation by AMLR was detected by 51Cr release assays 
using autologous or HLA-matched BLCL target cells infected with recombinant 
HIV/vaccinia viruses. Twelve subjects were tested for anti-HIV CTL activity against 
gag, pol, env and nef, with 6 testing positive against at least 1 antigen. In the control 
group described above, 11111 showed anti-HIV CTL activity against at least 1 antigen, x2 
with Yates correction = 5.09; p< .025 (data not shown). Figure 2 shows the cytotoxicity 
results for the 6 subjects with detectable anti-HIV CTL activity. Anti-HIV CTL activity 
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Figure 2. Anti-HIV CTL activity of 6 subjects with advanced HIV infection. The target 
cell legend depicted in the second pa!lel applies to all graphs. The number in the upper 
left hand comer of each graph corresponds to subject numbers in Table 1. 
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ranged from narrow (1 antigen) and weak (<25% specific lysis), to broad (>3 
determinants) and strong (>50% specific lysis). Anti-HIV CTL activity in the control 
group of HIV -infected individuals with > 1000 T cells/I-ll ranged over the same breadth 
and strength as the activity detected in the group with advanced HIV infection. In all 
cases the killing was blocked with anti-CD3 antibodies. This demonstrates that a 
substantial fraction of individuals with advanced HIV infection retain anti-HIV CTL 
memory responses. 
The CD28 phenotype of anti-HIV CTL was determined by 51 Cr release assays using 
effectors depleted of CD28+ cells, and in some cases, effectors enriched for CD28- T 
I 
cells. Results for subject (029) are shown in Figure 3. Depletion of CD28+ cells did not 
reduce killing (fig. 3a), while there was an increase in activity when the E:T ratio of 50:1 
was re-established with purified CD28- effector cells (fig. 3b). In this case, the killing 
activity was clearly confined to the CD28- population. This testing was performed for 4 
of the 6 subjects showing HIV-specific CTL activity (009, 029, 056, and 083). Ofthe 10 
anti-HIV CTL responses assessed, 8 were mediated predominantly by CD28-CD8+ CTL. 
Therefore, when present at this late stage of infection, HIV -specific CTL are 
predominantly CD28-. 
2.4.4 TCRPV gene family expression 
CD8+ TCR repertoire analysis was performed on 9 of the 13 subjects and, for 
comparison, on 6 uninfected controls. Six uninfected individuals were chosen as a 
control group for the TCR repertoire analysis as perturbations of the TCR repertoire have 
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Figure 3. Effects of depletion of CD28+ T cells (panel a) or enrichment of CD28- T cells 
(panel b) on the anti-HIV CTL activity of subject 029. Target cells were HLA Bw62-
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been reported at different stages of HIV infection and we wanted to compare TCR 
diversity in advanced infection with normal TCR diversity. Semi-quantitative RT-PCR 
was used to examine the relative levels of transcripts for 24 different TCR~V families . 
Relative expression levels were determined by expressing the specific ~V band intensity 
as a fraction of the internal control Ca band intensity. Figure 4 compares mean relative 
expression levels of each of the 24 TCR~V gene families in the control group to the 
group with advanced HIV infection. Significant differences between the 2 groups 
(p<0.05) were found for only one ofthe 24 TCR~V families; ~V2 (12.0% for controls vs 
8.6% for HIV-infected group). To assess individual differences in ~V gene family 
I 
relative expression levels, we compared each ~V gene family ofthe 9 HIV-infected 
subjects to the mean± 2 standard deviation range established for the uninfected control 
group. Of210 total reactions analyzed in this way, 201 fell within the established normal 
range. The 9 deviations involved 5 different subjects and 6 different ~V families. These 
results indicate that CD8+ TCR~V gene family expression levels are essentially normal in 
individuals with advanced HIV infection. 
2.4.5 TCR~V gene intrafamily diversity 
For a more detailed examination ofthe TCR repertoire, we performed junctional length 
diversity analysis within different TCR~V families. PCR amplification with ~V gene 
family and C~ specific primer pairs spanning the VDJ junction and separation of the 
products on sequencing gels reveals, on average, 6 to 9 different length polymorphisms in 
a normally diverse T cell repertoire [3 8] . We assessed junctional length diversity within 
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Uninfected HIV-infected 
Figure 5. TCRPV22 gene intrafamily junctional length diversity analysis comparing 3 
uninfected controls and 3 individuals with advanced HIV infection. Individual PV22 
gene family PCR products were separated on 6% polyacrylamide sequencing gels and 
visualized by silver staining. 
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14 pv families, and figure 5 shows results for one family CPV22) which are 
representative of our overall assessment. The number of individual bands visible was 
counted to assess overall diversity and no significant differences between the control and 
test group were found when the average number of bands in each family was compared. 
Stimulated cells were used to examine the diversity ofthe TCRPV repertoire in the HIV-
infected individuals and, although this might allow detection of rare spectratypes, it can 
not increase the overall diversity of the repertoire. All spectratypes observed were within 
the length polymorphism range exhibited by the circulating CDS+ T cells analyzed from 
the uninfected controls. From this data we conclude that overall CDS+ TCR repertoire 
diversity is largely maintained in advanced HIV infection. 
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2.5 Discussion 
In this study we investigated functional and genetic characteristics of the CD8+ T cell 
population in individuals with advanced HIV infection. The majority of CD8+ T cells 
persisting in this group expressed the T cell co-stimulatory molecule CD28, which has 
been linked with telomere length and replicative capacity [21-23]. CD8+ T cells from all 
individuals proliferated in vitro and differentiated into functional CTL. Both TCR~V 
' 
family expression levels and TCR~V gene intrafamily diversity levels largely fell within 
the same range as exhibited by uninfected controls. Together, these results indicate that 
from a general perspective, the functional and molecular genetic integrity of thb CD8+ 
population is maintained in advanced HIV infection. 
We also studied HIV-specific reactivity in the CD8+ T cell population in advanced HIV 
infection and found that half of the individuals tested retained inducible anti-HIV CTL 
activity against at least one of HIV gag, pol, env or nef Because HIV -specific CTL are 
thought to be important in controlling viral replication, the persistence of vigorous and, in 
some cases, diverse virus-specific memory CTL responses in subjects with advanced 
disease is somewhat paradoxical. The lack of detectable circulating CTL activity in these 
individuals indicates that no active CTL response is ongoing, despite high levels of 
viremia. One explanation for this is that CTL escape mutants have emerged, rendering 
the HIV -specific CTL detected at this stage ineffectual. The rapid rate of HIV replication 
combined with the high error rate of the R T enzyme produces a high mutation rate for 
HIV [39, 40]. Therefore, it is reasonable to speculate that mutations in CTL epitopes 
serve as a mechanism of immune escape. Although this has been questioned for HIV 
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infection, there is now considerable evidence showing that escape of HIV from CTL 
recognition plays a role in viral persistence [ 1, 15, 41-44]. This may be especially true 
where an oligoclonal HIV -specific CTL response involving recognition of only a single 
variable epitope develops. In these cases, HIV can easily escape and very rapid disease 
progression has been observed [44]. Emergence of CTL escape mutants has been 
demonstrated in primary infection [1, 42] and, in two cases, delayed immune escape was 
observed after 9-12 years of infection [ 15]. Together these reports clearly support the 
hypothesis that sequence variation serves as a mechanism of HIV escape from CTL. 
However, its unlikely that sequence variation alone accounts for the persistence of strong 
HIV -specific memory CTL responses in subjects with advanced disease. Tw~ of our 
subjects (056 and 091) had a diverse HIV-specific CTL response and simultaneous 
complementary mutations of multiple epitopes would be required for complete CTL 
escape. In cases such as this, it may be more likely that another mechanism, such as 
anergy or deprivation of CD4+ T cell help, renders the anti-HIV CTL ineffective. Since 
anergic cells usually regain responsiveness after a period of growth in IL-2 (45), our 
stimulation procedure would overcome this, but we have never observed much cell 
growth at all, let alone development of CTL function simply by exposing T cells from 
individuals at this stage of infection to IL-2. 
It is also possible that the HIV -specific CTL present at this stage of infection are CTL 
that have entered a state of replicative senescence on the verge of clonal exhaustion, and 
are ineffective in vivo. Our finding that anti-HIV CTL were predominantly CD28- lends 
some credence to this theory, however, the percentage of CD8+ T cells expressing CD28 
was comparable in fresh and stimulated cell cultures. This indicates that either CD28-
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cells replicate as efficiently as CD28+ cells, which would mean they were not all 
senescent cells, or that a proportion of the CD28+ population loses CD28 expression 
during culture in vitro. If so, the anti-HIV CTL memory cells could be predominantly 
CD28+ . For several individuals, we detected anti-HIV CTL of the same specificity on 
multiple occasions over a 12 month period in spite of a consistently high (>5log10/ml) 
plasma virus load, arguing against these cells being on the verge of antigen-driven clonal 
exhaustion. 
Six other individuals with advanced infection showed no detectable anti-HIV CTL 
activity on initial testing. It is possible that these individuals did have HIV -specific CTL 
f 
present at very low precursor frequencies or that were directed toward epitopes not 
expressed by the recombinant vectors used, but the lack of detectable activity in 50% of 
the individuals tested suggests anti-HIV CTL are clonally exhausted in some cases of 
advanced HIV infection. Exhaustion of anti-viral CTL has been shown to occur in mice 
infected with rapidly-replicating strains of lymphocytic choriomeningitis virus (LCMV) 
[ 46]. A similar situation could occur in HIV -infected individuals, where prolonged high-
level stimulation of activated effector CTL could produce clonal exhaustion by pushing 
cells beyond their replicative lifespan, [19, 47]. Studies have shown that CD8+ T cells of 
HIV -infected individuals have significant telomere shortening, indicating limited 
replicative reserve and the potential for clonal exhaustion [21 , 22]. There is also 
evidence that rapid exhaustion of HIV -specific CTL clones can occur during primary 
infection, with emergence of new dominant clones [27]. If exhaustion were to occur in 
the latter stages of disease, when T cell numbers are severely compromised, it may be 
impossible to generate new responses, resulting in a lack of inducible anti-HIV CTL 
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activity. However, in two cases where HIV -specific CTL were initially undetectable, a 
specific response became apparent following remission ofT cell lymphopenia, suggesting 
that reconstitution of HIV -specific CTL responses may still be possible even at this late-
stage of disease. Whether this inducible activity translates into an active, effective CTL 
response in vivo remains to be seen, but the fact that these individuals now show 
detectable circulating CTL activity as well is a positive sign. 
In summary, our results ,suggest that in advanced infection, HIV-specific CTL activity is 
selectively compromised while the functional and genetic integrity of the CDS+ T cell 
population as a whole remains intact. A substantial fraction of individuals with advanced 
f 
HIV infection retain anti-HIV CTL memory cells, however, these cells may be incapable 
of differentiating into effector CTL in vivo and further work is necessary to determine if 
these CTL recognize the contemporaneous endogenous HIV strains present. For other 
individuals, HIV -specific CTL are undetectable at this stage of disease. Therefore, 
multiple mechanisms appear to contribute to the loss of CTL activity in progressive HIV 
infection. However, the functional and genetic integrity of the CDS+ population as a 
whole is maintained, and since half of the HIV -infected individuals at this stage retain 
anti-HIV memory cells and another third regained HIV -specific CTL coincident with 
treatment-induced increases in T cell numbers, CTL-based immunotherapies for HIV or 
other pathogens remain plausible even in the advanced stages of HIV infection. 
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3.1 ABSTRACT 
The extent to which highly active antiretroviral therapy (HAART) restores human 
immunodeficiency v1rus (HIV)-specific immunity m advanced infection is unknown. 
Therefore, we studied how effective therapy affected HIV -specific CD8+ T cell responses 
in 4 individuals who had progressed to advanced infection. CD8+ T cell responses were 
assessed by cytotoxicity 'and interferon-gamma (IFN -y) production. Proliferative CD4+ T 
cell responses against HIV, Candida and mitogen were measured by 3H-thymidine 
incorporation. Substantial immune reconstitution indicated by increased CD4+ and CD8+ 
T cell numbers followed suppression of viral replication. This was associated with 
emergence of HIV -specific cytotoxic T lymphocytes (CTL), but only concurrent with 
detectable viral replic!ltion. Emergent anti-HIV CTL were similar to those at earlier 
stages of infection in terms of their specificity, function and CD28 phenotype. However, 
they were very short-lived in the absence of detectable HIV replication. Antigen-specific 
CD4+ T cell responses remained severely compromised. Thus, effective antiretroviral 
therapy restores the capacity for HIV -specific CTL responses after advanced infection. 
However, the transient nature of these responses suggests failure to generate stable long-
lived memory cells in the absence ofHIV-specific helper T cell responses. 
Keywords: HIV, HAART, cytotoxic T lymphocytes, Immune reconstitution 
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3.2 INTRODUCTION 
The central antiviral role of CDS+ T cells in simian immunodeficiency virus (SIV) 
infection has been clearly demonstrated (1 ,2) and many studies support a similar role for 
cytotoxic T lymphocytes (CTL) in human immunodeficiency virus (HIV) infection 
(reviewed in 3,4). The anti-HIV CTL response is remarkably strong and diverse, as HIV-
infected individuals often have high frequencies of CTL against many HIV epitopes 
(5,6). Untreated HIV infection almost invariably progresses to acquired Immtme 
deficiency syndrome (AIDS) as the levels and function of HIV -specific CTL diminish 
I (7 ,8). Several theories addressing the failure of CTL to durably suppress HIV replication 
include loss of HIV -specific CD4+ helper T cells (9, 1 0) and accumulation of CD8+CD28-
T cells with limited proliferative potential (11,12). Since virus and host co-exist for 
extended periods with many cumulative detrimental effects on the immune system, it is 
not surprising that multiple mechanisms might drive the ultimate failure of HIV -specific 
CTL. Whatever underlies this failure, it is important to determine if a 'point of no return' 
exists, beyond which HIV -specific CDS+ T cell responses are precluded, or if even 
following advanced HIV infection, immune reconstitution enables specific immune 
responses against HIV. 
Highly active antiretroviral therapy (HAART) can efficiently suppress viral replication, 
increase T cell numbers and promote immunity against certain opportunistic pathogens, 
even when initiated after advanced HIV infection (13-15). However, the degree of HIV-
specific immune reconstitution that can occur at this late stage is unknown. To address 
this issue, we followed HIV -infected individuals who had reached advanced infection 
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before responding to therapy, since any intractable defects imposed upon HIV -specific 
immunity over progressive HIV infection should be especially evident in this group. We 
previously characterized CDS+ T cell responses in a group of HIV -infected individuals 
with advanced infection (7). Four of these individuals subsequently responded to 
HAAR T with viral replication suppressed to undetectable levels and increases in their T 
cell counts. In this report, we describe associated changes in their HIV-specific CTL 
responses as well as their CD4+ T cell responses against Candida and HIV p24. 
For 2 individuals without anti-HIV CTL, HIV-specific CTL emerged following 
reconstitution of T cell numbers, but only transiently, in parallel with breakthroughs in 
viral replication. A third subject had undetectable HIV-specific CTL and viral load at all 
time points. The fourth subject retained diverse anti-HIV CTL while virus load remained 
detectable, even when T cell numbers were depressed, but rapidly lost HIV -specific CTL 
once virus replication became undetectable. Although these findings demonstrate that 
immune reconstitution enables HIV -specific CTL responses following advanced 
infection, the transient nature of these responses also illustrates the residual impact of 
cumulative immune defects imposed over the course of progressive HIV infection. 
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3.3 MATERIALS AND METHODS 
3.3.1 Study subjects 
Study participants were recruited through the Infectious Disease Clinic of the St. John's 
General Hospital, St. John's, NL, Canada. All had progressed to advanced HIV infection, 
defined by a total T cell count of <500/f.ll on consecutive clinic visits. At each visit 
clinical evaluation was performed, plasma HIV RNA was measured using Amplicor 
HIV-1 Monitor™ kits (Roche Diagnostic Systems Inc., Mississauga, Ontario, Canada) 
and peripheral blood lymphocyte (PBL) subsets were assessed by flow cyt(i)metry. 
Ethical approval was obtained from the Memorial University Faculty of Medicine Human 
Investigation Committee and all participants provided informed consent. 
3. 3. 2 Sample preparation 
Peripheral blood mononuclear cells (PBMC) were isolated from acid-citrate dextrose 
(ACD)-preserved fresh whole blood by density gradient centrifugation with Ficoll-paque 
lymphocyte separation medium (Pharmacia Chemicals, Dorval, Quebec, Canada). 
PBMC were washed twice in phosphate-buffered saline (PBS) containing 1% fetal bovine 
serum (FBS; Gibco, Grand Island, New York, USA), resuspended in lymphocyte medium 
(RPMI 1640 with 10% FBS, 10 mM Hepes, 2 mM L-glutamine, 1% 
penicillin/streptomycin, and 2x 1 o-s M 2-mercaptoethanol; all from Gibco) and counted. 
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Human leukocyte histocompatibility antigen (HLA) class I typing and generation of B 
lymphoblastoid cell lines (BLCL) were carried out as previously described (7). 
3. 3. 3 Cytotoxicity assays 
To activate anti-HIV CTL, approximately lx107 PBMC were stimulated by an 
-
autologous mixed lymphocyte reaction (AMLR), as previously described (7). HIV-
specific CTL activity w.as assessed against autologous or HLA-matched BLCL targets 
infected with the following recombinant vaccinia viruses: vVK1 (gag/poT), vDK1 (gag), 
vCF21 (poT), vPE16 (gp160), vTFnef(nef), and vSC8 (E. Coli p-galactosidase, control) 
1 (all from the NIH AIDS Research and Reference Reagent Program, Rockville, 
Maryland). Target cells were infected with 15 plaque forming units (pfu)/cell of the 
desired virus overnight, labeled for 90 minutes with 100 ~Ci Na251 Cr04 (Arnersham Life 
Sciences, Arlington, IL), washed 4 times with PBS containing 1% FBS, counted, and 
resuspended in lymphocyte medium. Effector and target cells (5000 cells/well) were 
incubated in duplicate in 96-well culture plates in a final volume of 300 ~1/well at 
effector:target (E:T) ratios of 50:1 , 25:1, and 12.5:1. Minimum and maximum release 
wells contained targets in medium alone or IN HCl respectively. After 5 hours 
incubation, 1 00 ~1 supernatant was removed and counted in a Wallac 1480 gamma 
counter. Percent killing was determined by the formula: 
(Test 5 1 Cr release - spontaneous release) x 1 00 I maximum 51 Cr release - spontaneous 
release. 
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Spontaneous release was always <25% and results were considered positive when percent 
specific 51 Cr release in the test wells was 2:10% above control wells. 
Peptide-sensitized targets were used to delineate epitopes recognized by anti-HIV CTL. 
Synthetic 20-mers at 40 )..lg/ml were incubated with 51 Cr-labeled target cells (5000/well) 
for 2 hours in 110 )..lllymphocyte medium. Effectors were then added at a 50:1 E :T ratio. 
Control wells contained effectors and targets without peptides. The volume of each well 
was adjusted to 300 )..ll and the 5 hour assay carried out as described. Overlapping gag 
(NIH AIDS Research and Reference Reagent Program) and nef (AIDS Reagent Project, 
Hertfordshire, England) peptides were tested. 
3.3.4 Lymphocyte separations 
CD28+ lymphocytes ~ere removed from effector populations immediately before CTL 
assays as previously described (7). To culture purified CD28-positive and negative CD8+ 
T cells, CD4+ lymphocytes were depleted from PBMC using magnetic beads coated with 
anti-human CD4 (Dynal Inc., Great Neck, NY, USA) at a 10:1 bead-to-target cell ratio 
prior to CD28+ T cell depletion as in (7). The resulting CD4-CD28+ (beaded) and CD4-
CD28- (unbound) populations were stimulated by AMLR, with irradiation of the PHA-
activated PBMC (3000 rads) before co-culture. Five days later, beads were removed 
from the CD4 ·cD28+ cell cultures by vigorous pi petting and magnetic removal of 
released beads. The beads were then washed twice by vigorous pipetting with PBS with 
5 mM EDTA and 0.1% bovine serum albumin (BSA, Sigma Chemical Co. , St. Louis, 
Missouri, USA). The unbound cells were pooled, centrifuged and recultured at lxl06/ml 
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in lymphocyte medium with 5 U/ml recombinant human interleukin-2 (IL-2; Hoffmann 
La Roche, Nutley, NJ, USA). 
3.3.5 Flow cytometry 
To determine the proportion of CD8+ T cells expressing CD28, PBMC were washed once 
in PBS containing 5 mM EDTA and 0.1% BSA and incubated for 20 minutes at 4°C with 
fluorescein isothiocyanate (FITC)-conjugated anti-CD3 (Dako Diagnostics, Mississauga, 
. 
Ontario), phycoerythrin (PE)-conjugated anti-CD28 and peridinin chlorophyll protein 
(PerCP)-conjugated anti-CD8 (Becton Dickinson). Samples were then washed, 
resuspended in 0.5% paraformaldehyde in PBS and analyzed on a F ACStarPius (Becton 
Dickinson). For intracellular staining, effector cells were incubated for 5 hours at 
500,000 cells per well in 1.0 rnl medium in 24-well culture plates at 5:1 ratio with 
autologous BLCL infected with recombinant HIV /vaccinia viruses. Ten !J.g/ml Brefelden 
A (Sigma Chemical Co.) was added for the final 4 hours. After incubation, cells were 
washed once and incubated for 20 minutes at 4°C with PerCP-conjugated anti-CD8 
(Becton Dickinson). Cells were then washed, fixed with 2% paraformaldehyde for 15 
minutes at 4°C, washed again and permeabilized with 0.2% saponin (Sigma Chemical 
Co.) in wash buffer, for 10 minutes at 4°C. The cells were washed once again and 
incubated for 20 minutes at 4°C with FITC-conjugated anti-interferon gamma (IFN-y) 
(Caltag Laboratories, Burlingame, California), or FITC-conjugated isotype-matched 
controls. Samples were washed again, resuspended in 1% paraformaldehyde in PBS and 
analyzed on a F ACStallus analyzer (Becton Dickinson). 
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3. 3. 6 Proliferation assays 
Lymphocyte proliferation assays were carried out by resuspending PBMC in lymphocyte 
medium with 10% human AB serum (ICN Biomedicals Inc., Aurora, Ohio) replacing 
FBS. Cells were incubated at 100,000/well in triplicate in 200 f.ll in 96-well culture 
plates. Negative control wells included 2 f.lg/ml ~-galactosidase (VWR Canlab, 
Mississauga, ON) or medium alone, while positive control wells contained 5 flg/ml 
purified phytohemagglutinin (PHA-P; Wellmark Diagnostics, Guelph, Ontario, Canada). 
Test wells contained 2 f..!g/ml Candida albicans (Greer Laboratories Inc., Lenoir, NC) or 
HIV p24 (Virogen, Watertown, MA). After 5 days, wells were pulsed with 1 J..!Ci 3H-
thymidine (Perkin Elmer Life Sciences Inc. , Boston, MA) and 16 hours later were 
harvested onto filter mats using a Tomtec Harvester96 and counted on a Packard 
TopCount beta counter. Stimulation indices were determined by dividing 3H-thymidine 
incorporation in test wells by that of negative control wells. 
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3.4 RESULTS 
3. 4.1 Subject characteristics 
Table 1 shows age, gender, duration of follow-up, and early and late CD4+ and CD8+ T 
cell counts for the individuals studied. All_ were initially considered in advanced HIV 
infection with total T cell counts <S00/1-.d peripheral blood. Two had previous AIDS 
defining illnesses (cytomegalovirus retinitis; 028, mycobacterium avium complex; 069). 
With varying patterns, control of viral replication and at least partial restoration ofT cell 
counts occurred for all subjects. Changes in T cell counts and HIV virus load ovFr time 
are shown in figure 1 a-d. All subjects received HAART consisting of a protease inhibitor 
(PI) and at least 2 nucleoside analogue reverse transcriptase inhibitors. 
3. 4. 2 Changes in HIV-specific CTL Activity 
Results of HIV -specific CTL assays are indicated in figure 1 a-d by plus or minus signs 
directly below the x-axes; pluses indicate a positive response against at least one HIV 
antigen tested (gag, pol, env, and nef), while minus signs indicate no detectable HIV-
specific CTL activity at that time. 
While T cell counts remained very low, only subject 083 had detectable anti-HIV CTL. 
Diverse activity against gag, pol, and nef, was detected on four occasions over the first 
year of study. Antiretroviral treatment increased T cell numbers over this period, but 
only partially suppressed virus replication. Once full control of virus replication 
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Table 1. General Characteristics ofHAART-related Immune Reconstitution in This 
Subject 
ID 
028 
069 
079 
083 
aMonths 
of 
Age Sex follow-up 
32 M 53 
46 M 51 
30 F 51 
34 M 38 
Study 
CD4+ T cells 
Per ~1 blood 
bEarly Late 
4 247 
46 184 
48 348 
121 334 
CD8+ T cells 
per ~1 blood 
Early Late 
94 1143 
266 510 
226 480 
347 574 
%CD8+CD28+ 
T cells 
Early Late 
75 42 
28 45 
75 84 
44 48 
aMonths of follow-up refers to the total length oftime the individual has been under 
observation since emolling in study. 
bEarly and late CD4+ and CD8+ T cell counts/~1 peripheral blood are averages of the first 
2 (early) and last 2 (late) such measures available for each participant. 
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occurred, HIV-specific CTL became undetectable (figure la). Subject 079 had no 
detectable HIV -specific CTL or viral load at any time. HAART initiated prior to the start 
of this study had controlled virus replication and while continued therapy increased T cell 
counts, HIV -specific CTL never became detectable (figure 1 b). 
Subjects 028 and 069 showed similar patterns of HIV-specific CTL activity, T cell 
reconstitution and viral replication. Both initially had very low T cell counts and 
detectable virus replication, but no HIV-specific CTL (figure lc and ld). Over several 
months of effective therapy, T cell counts increased and plasma virus load became 
undetectable. HIV -specific CTL were detected subsequent to partial T cell restoration 
only when breakthroughs in viral replication occurred. This CTL activity rapidly 
disappeared as control of viral replication was reestablished. Subject 028 experienced a 
brief breakthrough in virus replication concurrent with HIV -specific CTL activity that 
persisted for 3 months (figure lc). Subject 069 experienced a more sustained 
breakthrough in viral replication. Anti-HIV CTL against gag and nef were detected 
shortly before the breakthrough and when virus replication persisted, the response 
broadened to include pol. Shortly after this, virus load again became undetectable and all 
HIV-specific CTL disappeared (figure ld). These results indicate that following 
advanced HIV infection, development of new CTL responses depends on immune 
reconstitution, and that persistent antigenic stimulation is required to maintain HIV-
specific CTL activity. 
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Figure 1. Changes in T cell counts and plasma HIV RNA levels for 4 individuals with 
severe lymphopenia prior to responding to antiretroviral therapy. Pluses and minuses 
directly below the x-axis indicate time points at which HIV -specific CTL activity was 
present(+) or absent(-). On they-axis, a viral load of'O' indicates viral replication 
below detection limits of the assay, which changed from log10 2.6 to log10 1.7 copies/ml 
during the course of study. Subjects are identified in the upper right comer of each graph 
and the duration of study for each individual is provided in Table 1. 
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3. 4. 3 Characterization of emergent anti-HIV CTL 
To further characterize the emergent anti-HIV CTL of subjects 028 and 069, we 
identified the specific epitopes recognized and assessed IFN-y production by the HIV-
specific CD8+ T cells of subject 069. We tested CTL from subject 069 against 7 gag and 
9 nef peptides, each containing a CTL epitope presented in association with one of the 
subjects' HLA class I antigens (A3, A28; B7, B8). One gag (321-340) and one nef 
peptide (81-100) containing the previously identified HLA-B8 restricted CTL epitopes 
gag 329-337 and nef87-95 were recognized (fig. 2a). Approximately 4% of the subjects' 
CD8+ T cells produced IFN-y specifically in response to HIV gag/pol (fj.g. 2b). 
Therefore, emergent HIV-specific CD8+ T cells from subject 069 mediated both 
cytotoxicity and IFN-y production. For subject 028 (HLA class I: A2; B35, Bw62) five 
9-mer pol peptides containing epitopes presented by HLA-A2 or -B35 were tested. One 
positive response against the previously identified HLA-A2 restricted pol 334-342 CTL 
epitope was detected (data not shown). Therefore, emergent anti-HIV CTL from subjects 
028 and 069 were directed against commonly-recogniz~d HIV epitopes. 
3.4.4 CD28 phenotype ofCD8+ T cells 
Several studies at earlier stages of HIV infection reported increased proportions of CD8+ 
T cells expressing CD28 with effective suppression of HIV replication (16, 17). In 
contrast to the earlier stages of HIV infection, we found high proportions of CD28+CD8+ 
T cells in advanced infection (7). Therefore, we wanted to see what happened to this T 
cell subset with effective viral suppression following advanced infection. Table 1 shows 
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Figure 2. Characterization of emergent HIV -specific CTL. (a) Cytotoxicity of 069 
AMLR-generated effector cells against autologous BLCL sensitized with HIV gag and 
nefpeptides. (b) Intracellular IFN-y production of069 AMLR-generated CD8+T cells 
stimulated by autologous BLCL infected with recombinant vaccinia viruses expressing 
p-galactosidase (vSC8) or HIV gag/pol (vVKl). 
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proportions of CD8+ T cells expressing CD28 at early and late time points for each 
individual. Subject 028, with the largest increase in CD8+ T cell numbers, had a 
declining proportion of CD8+ T cells expressing CD28, while subject 069 showed an 
increasing proportion. The two remaining subjects showed little change. These results 
demonstrate variability in the CD28 phenotype of CD8+ T cells contributing to immune 
reconstitution in advanced HIV infection. 
3.4.5 CD28 phenotype of HIV-specific memory CTL 
We previously reported that HIV -specific CTL present during advanced infeqion are 
predominantly CD28 negative, a phenotype associated with terminal differentiation and 
reduced proliferative potential (7). To determine how this would affect emergent anti-
HIV CTL responses in individuals with advanced HIV infection, we investigated the 
CD28 phenotype of precursor and effector anti-HIV CTL. For subjects 083 (fig. 3a) and 
069 (fig. 3b) effectors were depleted of CD28+ cells immediately before CTL assays to 
determine the CD28 phenotype of effector anti-HIV. CTL. For subject 028 (fig. 3c), 
PBMC were first depleted of CD4+ cells, and then CD28-positive and negative cells 
isolated. The resulting CD4-CD28+ and CD4-CD28- populations were stimulated 
separately and tested for HIV (gag/pol)-specific CTL to determine the CD28 phenotype 
of the precursor anti-HIV CTL proliferating and or differentiating in vitro to generate 
effector anti-HIV CTL. We chose subject 28 for the in vitro restimulation of isolated 
CD28+ and CD28- CD8+ T cells because of his higher CD8+ T cell counts after immune 
recovery (Table 1) and the need for sufficient starting cell numbers in each subset for 
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Figure 3. Contribution of CD28+ cells to anti-HIV CTL activity. Non-manipulated 
effector cells (total, dark symbols) and effector cells depleted of CD28+ cells (CD28- , 
open symbols) immediately before testing (083, 069) or prior to in vitro stimulation (028) 
were tested for killing of target cells infected with recombinant vaccinia viruses expressing 
HIV proteins: vDKl , HIV gag; vCF21 , HIV pol; vTFnef, HIV nef; vVKl, HIV gag/pol. 
Killing of targets infected with a recombinant vaccinia virus expressing ~-galactosidase (vSC8) 
was subtracted. Subjects are identified in the upper right corner of each graph. 
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effective in vitro restimulation. For all 5 CTL responses examined, effector CTL activity 
was distributed fairly evenly between CD28+ and CD28- T cell subsets (fig. 3). Before 
immune reconstitution, the ongoing anti-HIV CTL response of subject 083 involved 
predominantly CD28-CD8+ T cells (7) . For subject 028, CD28+ and CD28- cultures had 
equal CTL activity against HIV gag/pol, demonstrating CD8+CD28+ and CD8+CD28-
HIV -specific CTL precursors. Therefore, in terms of CD28 phenotype, HIV -specific 
CTL precursors and effectors emerging following advanced HIV infection and partial 
immune reconstitution were similar to those present earlier in infection. 
3. 4. 6 T cell proliferation 
An association between CTL activity and specific CD4+ helper T cell responses has been 
reported in HIV infection (18). Therefore, we assessed T cell proliferation against 
mitogen (PHA), recall antigen (Candida albicans), and HIV p24 at 2 time points 
following partial immune reconstitution and suppression of viral replication. No 
responses to p24 were detected and only one subject (069) responded to Candida (fig. 4). 
However, all responded to PHA with stimulation indices >30 (data not shown). 
Therefore, although their T cells proliferated in response to a mitogen, antigen specific 
CD4+ T cell responses remained severely compromised in this group. 
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Figure 4. Antigen-specific T cell proliferation following immune reconstitution. At 2 
separate time points, specific proliferation in response to Candida antigens or HIV p24 
was measured. Stimulation indices above 3 were considered to indicate a positive helper 
T cell response against that antigen. 
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3.5 DISCUSSION 
The ability of HAART to increase T cell numbers and reconstitute anti-HIV CD8+ T cell 
responses at earlier stages of infection is well documented (19-21). However, little is 
known about the potential to reestablish HIV specific immunity in individuals reaching 
advanced HIV infection. In this study we examined the impact of effective suppression 
of viral replication on generalized immune reconstitution and anti-HIV T cell responses 
in individuals previously progressing through advanced infection. Despite the small 
number of appropriate subjects available to address this question, we found consistent 
features of HIV -specific CD8+ T cell responses in this group that have general 
implications for the requirements of stable CTL memory and the prospects for immune-
based therapy in advan~ed infection. The most notable feature of HIV -specific CD8+ T 
cell responses in this group was strict dependence upon ongoing antigenic stimulation for 
their persistence. Both ongoing responses and those emerging with effective therapy 
diminished beyond detection within several months of effective viral suppression. 
Consistent with this finding, anti-HIV CTL were never detected from one subject with an 
undetectable virus load throughout the study, despite significant immune reconstitution. 
Our findings clearly indicate that improving the immunological status of individuals 
previously reaching advanced HIV infection allows emergence of anti-HIV effector CTL. 
However, at least initially, this response occurs without concurrent generation of stable 
memory CTL. 
Defective generation of memory CTL has also been reported at earlier stages of HIV 
infection (22), but the absolute short-lived nature of emergent responses following 
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advanced infection was striking. Since the CD2S phenotype of CDS+ CTL has been 
associated with their stage of differentiation and anticipated lifespan (11, 12), we assessed 
the distribution of CTL and CTL precursors within CD2S+ and CD2S- CDS+ T cell 
subsets. After some degree of immune reconstitution, the distribution of CD2S+ effectors 
and precursors was similar to earlier stages of infection, suggesting that cells with the 
potential for greater proliferation and longer lifespan were being recruited against HIV 
(7,23). With regard to fine specificity and antigen-specific IFN-y release, emergent HIV-
specific CTL activity was also indistinguishable from earlier stages of infection. 
One possible explanation for transient anti-HIV CTL responses in this group is the impact 
of other immunological factors on activation of CTL and stable generation of memory 
cells. Differential conditioning of antigen-presenting cells (APC) can determine whether 
CDS+ T cells are act~vated appropriately or steered towards premature decay (24,25). 
Circulating dendritic cell precursors are reduced in advanced HIV infection and the effect 
of HAART on reconstitution of these critical APC is unknown (26,27). In murine 
lymphocytic choriomeningitis virus (LCMV) infection, CDS+ anti-LCMV CTL are 
activated in the absence of help from CD4+ T cells, but without generation of long term 
CTL memory (2S). Furthermore, based on collected data and mathematical modeling, 
Wodarz et al suggest that with CD4+ T cell help, CTL responses persist with very little 
antigen, yielding long-term control of infection (29). Conversely, without specific CD4+ 
T helper responses, they suggest CTL require high antigen levels to persist and do not 
control infection in the long term. The transient anti-HIV CTL responses we detected 
exclusively in concert with breakthroughs in viral replication corroborate previous 
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findings and this proposed model. Despite substantial increases in total CD4+ T cells and 
strong responses to mitogens, specific CD4+ T cell responses to an unrelated recall 
antigen and to HIV itself were absent or very weak in our subjects. Therefore, the failure 
to generate long-lived HIV-specific CD8+ T memory cells together with effector CTL 
may reflect HIV -specific CD4+ T cell deficiencies. Whether this inability to maintain 
-
CD8+ T cell memory without replicating virus is confined to individuals reaching 
advanced HIV infection, or common to all chronically-infected subjects, is an important 
question. 
Although there have been suggestions of a narrow window period during which treatment 
I 
for HIV need be applied to preserve immune responses (30), our data demonstrate that 
even after HIV infection progresses to extreme T cell lymphopenia, successful treatment 
and partial immune reconstitution can revive HIV -specific CD8+ T cell responses. How 
the activity we detected in vitro reflects in vivo activity and what impact the HIV -specific 
CD8+ T cells have in vivo at this stage is unknown. However, the consistent association 
between CTL activity and viral replication and the broadening of CTL activity when 
virus replication continued suggests the CTL activity detected reflects adaptive responses 
to in vivo viral replication. While revitalization of CD8+ T cell responses following 
HAAR T in this group extends the potential for immune therapy to individuals with 
advanced HIV infection, the transience of emergent responses underlines limitations of 
immune therapy. Allowing limited viral replication through treatment interruption may 
efficiently activate HIV -specific CD8+ T cells, but the risk of eradicating or aborting 
HIV -specific CD4 + T cell responses may outweigh any benefits, especially if the CD8+ T 
cell response is transient. The severity of this risk was recently clarified by 
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demonstration that HIV selectively infects HIV -specific CD4+ T cells (31 ). If, as both 
experimental data and theoretical considerations suggest, durable emergent CD8+ T cell 
responses require concurrent help from CD4+ T cells, strategies to reactivate CD4+ HIV-
specific T cell responses should be developed. Remune TM or other vaccine formulations 
that activate HIV -specific CD4+ T cells without exposure to virus may be useful (32). 
Likewise, using interleukin-2 (IL-2) to raise CD4+ T cell numbers prior to vaccination 
could increase the possibjlity of activating HIV -specific helper T cells (33,34). However, 
there are indications that following the severe CD4+ T cell depletion of advanced HIV 
infection, certain immune defects, such as reduced T cell proliferation and increased T 
f 
cell activation, persist even after CD4+ T cell reconstitution occurs (35,36). The extent of 
these defects is associated with nadir CD4+ T cell counts, indicating that advanced HIV 
infection imposes a lingering immunological effects not simply overcome by viral 
suppression and numerical reconstitution ofT cell subsets. The nature of these lingering 
defects and their relationship to nadir CD4 + T cell counts warrants further investigation. 
In summary, our results show that HAART can restore T cell numbers and the capacity 
for HIV -specific CTL responses following advanced HIV infection. However, emergent 
anti-HIV CTL responses were only detected in close proximity to breakthroughs in viral 
replication. The emergent CTL responses were normal in terms of CD28 phenotype, 
specificity, cytotoxicity and cytokine release, but rapidly disappeared once viral 
replication became undetectable. Failure to generate appropriate memory cells under 
these circumstances may reflect a lack of HIV specific helper T cells. Thus, advanced 
HIV infection, successfully treated, provides a unique system for identifying important 
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determinants of memory T cell generation and preservation, and for developing immune 
therapies beneficial at all stages of HIV infection. 
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4.1 Abstract 
During HIV infection, CD8+ T cells lacking the costimulatory molecule CD28 increase in 
number and proportion. This accumulation is associated with disease activity and 
possibly with CD8+ T cell dysfunction. In this study, CD8+CD28+ and CD8+CD28- T 
-
cells from 41 HIV -infected individuals at various stages of disease were compared in 
terms of HIV -specific cytotoxicity, TCR~V repertoire diversity, and cytokine production. 
We found that the CD28 phenotype of anti-HIV CTL evolves in parallel with disease 
progression and disease activity. Absolute numbers of CD4+ T cells and CD4+/CD8+ T 
, 
cell ratios progressively decreased in 3 groups with an increasing prevalence of CD28-
HIV -specific CTL. Conversely, HIV replication levels progressively increased in parallel 
with the prevalence of CD28- HIV -specific CTL. Repertoire diversity at the level of 
TCR~V gene family expression was maintained at normal levels for both CD28+ and 
CD28- T cells at all stages of infection. Diversity at the level of junctional length 
polymorphism was more restricted in the CD8+CD28- T cell population, but this 
difference remained relatively constant through differe~t stages of infection. Both CD28+ 
and CD28- T cells produced IL-2 and IFN-y, regardless of disease stage and/or the 
predominant CD28 phenotype of anti-HIV CTL. 
Keywords: CD28, HIV, Cytotoxic T Lymphocytes 
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4.2 Introduction 
The CD28 cell-surface accessory molecule provides secondary signals critical for 
appropriate activation of naive CD4+ and CD8+ T cells1• At birth, CD28 is expressed on 
virtually all peripheral blood T cells, suggesting that CD28 expression is the default 
condition for naive thymus-derived T cells2 . In acute viral infections, there is often 
considerable rapid expansion of CD8+CD28- antiviral effector T cells3. Upon antigenic 
stimulation, these CD8+CD28- T cells produce interferon gamma (IFN-y), but not 
interleukin-2 (IL-2) and proliferate poorly4'5 . This fueled suggestions that CD28- cells 
can be unresponsive or at least require enhanced costimulation for full activation16• The 
proportion of CD8+ T cells expressing CD28 also decreases with age and expanded 
oligoclonal populations of memory T cells in elderly individuals always lack CD28 
expression 7-9. This indicates that repeated or prolonged antigenic experience can 
eventually eliminate CD28 expression even on resting memory cells. These CD8+CD28-
T cells have shortened telomeres reflecting an extensive history of cell division 
culminating in replicative senescence10. Thus, the CD8+CD28- T cells in peripheral 
blood are not a uniform population. While some may be functionally effete remnants of 
past immunological battles, others may be actively engaged in ongoing cell-mediated 
anti-viral immune responses. Chronic viral infections, where there is persistent activation 
of CD8+ T cells, are one situation where the proportion of CD8+ T cells expressing CD28 
could have a variety of meanings and implications in relation to disease activity and 
progression. 
12 1 
In HIV infection, CD28- T cells often comprise more than 60% of the peripheral blood 
CD8+ T cell population5' 11 • Expansion of the CD8+CD28- T cell subset initially occurs 
during primary infection and persists throughout the natural course of disease12• Most 
CD8+CD28- T cells in HIV -infected individuals express activation markers, such as 
CD38 and HLA-DR, indicative of terminally differentiated effector T cells13 . However, 
we and others have shown that there are also CTL precursors within the CD28-
population that proliferate and differentiate in vitro in response to antigenic 
stimulation14' 15. Identical CD8+ CTL clones occur within both the CD28+ and CD28-
subsets of HIV -infected individuals and radioactive labeling and tracing of T cells 
showed clearly that CD28+ T cells generate CD28- progeny16' 17. Effective antiretroviral 
therapy lowers the proportion of CD8+CD28- T cells and shifts the majority of HIV-
specific CD8+ T cells detectable by tetramer staining from the CD28- to the CD28+ 
population18' 19. These data suggest that the predominance of CD8+CD28- cells in HIV 
infection reflects continuous differentiation of CD8+CD28+ T cells into effector cells in 
response to chronic viral stimulation. Therefore, the CD8+CD28- T cell population 
present in HIV infection may reflect the mixed accumulation of active effector cells and 
effete senescent cells. It is important to determine whether characteristics of the 
expanded CD8+CD28- T cell population evolve to reflect the CD8+ CTL dysfunction 
associated with progressive HIV infection. The aim of this study was to compare 
CD8+CD28+ and CD8+CD28- T cells at different stages of HIV disease progression in 
terms of their relative contribution to HIV -specific cytotoxicity, TCR~V chain repertoire 
diversity and cytokine production capacity. 
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4.3 Materials and Methods 
4.3.1 Study subjects 
Study participants were recruited through the Infectious Disease Clinic of the St. John's 
General Hospital, St. John's, NL, Canada. At each visit clinical evaluation was 
performed, plasma HIV RNA was measured using Amplicor HIV-1 Monitor™ kits 
(Roche Diagnostic Systems Inc., Mississauga, Ontario, Canada) and peripheral blood 
lymphocyte (PBL) subsets were assessed by flow cytometry. Ethical approval was 
obtained from the Memorial University Faculty of Medicine Human Investigation 
Committee and all participants provided informed consent. 
4.3.2 Sample preparation 
Peripheral blood mononuclear cells (PBMC) were isolated from acid-citrate dextrose 
(ACD)-preserved fresh whole blood by density gradient centrifugation with Ficoll-paque 
lymphocyte separation medium (Pharmacia Chemicals, Dorval, Quebec, Canada). 
PBMC were washed twice in phosphate-buffered saline (PBS) containing 1% fetal bovine 
serum (FBS; Gibco, Grand Island, New York, USA), resuspended in lymphocyte medium 
(RPMI 1640 with 10% FBS, 10 mM Hepes, 2 mM L-glutamine, 1% 
penicillin/streptomycin, and 2x10-5 M 2-mercaptoethanol; all from Gibco) and counted. 
Generation of B lymphoblastoid cell lines (BLCL) from study participants was carried 
out as previously described14. 
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4.3.3 Lymphocyte stimulation 
To activate and expand anti-HIV CTL, approximately lx107 PBMC were stimulated by 
an autologous mixed lymphocyte reaction (AMLR) as previously described14. 
4.3.4 Lymphocyte separations 
CD28+ lymphocytes were removed from AMLR stimulated effector populations for 
cytotoxicity assays, and ' from freshly-isolated PBMC for intracellular flow cytometry 
staining with purified anti-CD28 (leu28 Beckton Dickinson, Mississauga, Ontario) 
followed by goat anti-mouse IgG coated magnetic beads (Dynal Inc., Great Neck, New 
I 
York), as previously described 14• The resulting CD28- (unbound) cells were resuspended 
at effector to target (E:T) ratios based on starting cell numbers for use in the assays. 
Flow cytometry reveal~d that this depletion method removed more than 98% of CD28+ T 
cells (data not shown). 
For TCR~V gene repertoire analysis CD4+ T cells were depleted from PBMC using 
magnetic beads coated with anti-human CD4 (Dynal Inc.) at a 10:1 bead-to-target cell 
ratio prior to CD28+ T cell depletion. The resulting CD4-CD28+ (beaded) and CD4-
CD28- (unbound) populations were frozen at -70°C for subsequent RNA extraction and 
analysis. Flow cytometry prior to freezing revealed that depletion resulted in removal of 
more than 98% of CD4+ and CD28+ T cells (data not shown). 
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4.3.5 Cytotoxicity assays 
HIV -specific CTL activity was assessed against autologous or human histocompatibility 
linked antigen (HLA)-matched BLCL targets infected with the following recombinant 
vaccinia viruses: vVK1 (gag/pol); vDK1 (gag); vCF21 (pol); vPE16 (gp160); vTFnef 
(ne/) and vSC8 (E. Coli ~-galactosidase, control) (all from the NIH AIDS Research and 
Reference Reagent Program, Rockville, Maryland). Target cells were infected with 15 
plaque forming units (pfu)/cell of the desired virus overnight, labeled for 90 minutes with 
100 !lCi Na251 Cr04 (Amersham Life Sciences, Arlington, IL), washed 4 times with PBS 
containing 1% FBS, counted, and resuspended in lymphocyte medium. Effector and 
target cells (5000 cells/well) were incubated in duplicate in 96-well culture plates in a 
final volume of 300 Ill/well at E:T ratios of 50:1 , 25:1, and 12.5:1. Minimum and 
maximum release wells contained targets in medium alone or IN HCl respectively. After 
5 hours incubation, 1 00 Ill supernatant was removed and counted in a Wallac 1480 
gamma counter. Percent killing was determined by the formula: 
(Test 51Cr release - spontaneous release) x 100 I maximum 51 Cr release - spontaneous 
release. 
Spontaneous release was always <25% of maximum release and results were considered 
positive when % specific 51 Cr release in the test wells was ~ 10% above control wells. 
4.3.6 T cell repertoire analysis 
RNA was extracted from CD4-CD28+ (bead bound) and CD4-CD28- (unbound) T cell 
populations with Trizol (Gibco BRL, Burlington, Ontario) as per the manufacturer' s 
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instructions. TCRPV gene family relative expression levels were assessed by semi-
quantitative reverse transcriptase polymerase chain reaction (RT-PCR) as previously 
described14. Intrafamily junctional length diversity was assessed by separation of the 
PCR products on sequencing gels and visualization by silver staining. 
4.3. 7 Flow Cytometry 
To determine the proportion of CD8+ T cells expressing CD28, PBMC were washed once 
in PBS containing 5 mM EDTA and 0.1% bovine serum albumin (BSA; Sigma Chemical 
Co., St. Louis, Missouri) and incubated for 20 minutes at 4°C with fluorescein 
I 
isothiocyanate (FITC)-conjugated anti -CD3 (Dako Diagnostics, Mississauga, Ontario), 
phycoerythrin (PE)-conjugated anti-CD28 (Becton Dickinson), and Peridinin Chlorophyll 
Protein (PerCP)-conj~gated anti-CD8 (Becton Dickinson). Samples were washed once 
after staining, resuspended in 0.5% paraformaldehyde in PBS and analyzed on a 
F ACStarPlus analyzer (Becton Dickinson) after excitation at 488 run with an argon laser. 
For intracellular staining, effector cells were incubated overnight at 1 x 1 06 cells per well 
in 1 ml medium in 24-well culture plates with 50 ng/ml phorbol 12-myristate 13-acetate 
(PMA; Biomol, Plymouth Meeting, Pennsylvania), 2.5 )-lg/ml ionomycin (ICN 
Biomedicals Inc., Irvine, California), and 10 )-lg/ml brefelden A (Sigma Chemical Co.). 
The next morning each culture well was divided into three aliquots for staining. All were 
surface stained with PE-conjugated anti-CD8 (Caltag Laboratories, Burlingame, 
California), fixed with 2% paraformaldehyde in PBS for 15 minutes at 4 °C, and 
permeabilized with 0.2% saponin (Sigma Chemical Co.) in wash buffer for 10 minutes at 
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4°C. Cells were washed once and stained for 20 minutes at 4°C with FITC-conjugated 
anti-IFN-y, FITC-conjugated anti-IL-2, or FITC-conjugated isotype matched controls (all 
from Caltag Laboratories). Samples were washed again, resuspended in 1% 
paraformaldehyde in PBS and analyzed on a F ACStarPlus analyzer as above. 
4.3.8 Statistical Analysis 
Normal distribution of ' data was confirmed by the Kolmogorov-Smirnov test and 
differences in the mean values of various parameters compared between groups were 
assessed using Student's t-test. Correlation between different continuous variables was 
assessed by linear regression. 
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4.4 Results 
4.4.1 Subject Characteristics 
Forty-one HIV -infected subjects at various stages of disease participated in this study. 
Most (61 %) were receiving antiretroviral therapy at the time of testing. Their CD4+ T 
-
cell counts ranged from 0-1249 cells/J .. tl blood (mean= 398 cells/ J..Ll) and their CD8+ T cell 
counts ranged from 65-2400 cells/J..Ll blood (mean = 903 cells/J..Ll). Fourteen individuals 
(34%) had <200 CD4+ T cells/ J..Ll blood, 18 (44%) had between 200 and 500 CD4+ T 
cells/ J..Ll blood, and 9 (22%) had more than 500 CD4+ T cells/ J..Ll blood. Virus load 
f 
measurements ranged from undetectable (<1.7 log10 copies HIV RNA/ml plasma) to 5.9 
log10 copies/ml plasma (mean = 3. 7 log10 copies/ml). The proportion of CD8+ T cells 
lacking CD28 expression ranged from 17%-82% (mean = 55%). CD28 negative cells 
accounted for >60% of the CD8+ T cell population in 21 subjects. Therefore, our study 
cohort represented a broad cross-section of HIV disease status in terms of both ongoing 
disease activity and the cumulative impact of disease progression on T cell subsets20. 
4.4.2 Cytotoxicity Assays 
The CD28 phenotype of anti-HIV CTL generated by in vitro stimulation was examined 
for 30 subjects. Figure 1 shows HIV-specific CTL assay results for representative 
subjects from each of 3 groups distinguished by the predominant CD28 phenotype of 
their anti-HIV CTL. For 11 of the 30 individuals, HIV -specific CTL were predominantly 
CD28+ (table 1, group 1) as HIV -specific cytotoxicity > 10% above background was 
detected within the unmanipulated cell population only (figure 1a). Twelve individuals 
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Figure 1. Anti-gag/pol activity ofunmanipulated (solid symbols) and CD28+T 
cell-depleted (open symbols) populations for 1 representative individual from each of 
group 1 (predominantly CD28+ CTL), group 2 (CD28+ and CD28- CTL), and group 3 
(predominantly CD28- CTL). Background lysis (cytotoxicity against targets infected 
with V sC8) has been subtracted. 
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had anti-HIV CTL distributed equally between the CD8+CD28+ and CD8+CD28- T cell 
subsets (table 1, group 2) with HIV -specific cytotoxicity >20% above background within 
the unmanipulated population and > 10% above background within the CD28- population 
(figure 1 b). In this group specific cytotoxicity always fell by at least 10% when CD28+ 
cells were depleted. The remaining 7 subjects had exclusively CD28- HIV -specific CTL 
(table 1, group 3) with HIV specific cytotoxicity unaffected by removal of CD28+ T cells 
(figure 1c). 
To address the potential significance of the predominance of CD28- or CD28+ anti-HIV 
CTL, we compared other relevant characteristics of groups 1, 2 and 3 defined as above. 
f 
Table 1 shows the range, mean, and standard deviation for several immunological and 
virological parameters compared between the 3 groups. We found significant differences 
in mean CD4' T cell counts (group 1 versus group 2, p = 0. 007, group 1 versus group 3, p 
. 
= 0.003), mean CD4/CD8 T cell ratios (group 1 versus group 2, p = 0.002, group 1 versus 
group 3, p = 0.003) and mean virus load measurements (group 1 versus group 3, p = 
0.00008, group 2 versus group 3, p = 0.0008). These results outline a strong relationship 
between the predominant CD28 phenotype of anti-HIV CTL, disease progression (CD4+ 
T cell count and CD4+/CD8+ T cell ratio) and disease activity (virus load), with 
increasing proportions of CD28- anti-HIV CTL paralleling disease progression and 
activity. Neither total CD8+ T cell counts, nor the proportion of circulating CD8+ T cells 
expressing CD28 differed significantly between any of the 3 groups. Each of the 
parameters compared between groups 1, 2 and 3 was tested for correlation with the 
percentage of CD28- anti-HIV CTL by linear regression and significance determined 
from the correlation coefficient (r). For the entire group of 30 individuals, we found 
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Table 1. Characteristics of groups of individuals with differing proportions of CD28+ 
HIV -specific CTL 
Group 1 n = 11 Group 2 n= 12 Group 3 n=7 
Parameter Range Mean±SD Range Mean±SD Range Mean±SD 
CD4+ T cells/ 1-.tl blood 149-1249 620 ± 342 14-646 320 ± 182 0-474 181 ± 179 
CDS+ T cellsf!..tl blood 227-1240 774 ± 315 65-1932 1012 ± 622 215-1304 680 ± 381 
CD4:CD8 ratio 0.3-1.9 0.9 ± 0.5 0.2-1.0 0.4 ± 0.3 0-0.7 0.3 ± 0.3 
Virus loadt 1.7-3.8 3.0 ± 0.5 1.7-4.7 3.3 ± 0.6 3.6-5.9 4.6 ± 0.9 
%CD8+ T cells CD28+ 37-77 49 ± 14 18-74 43 ± 15 25-61 38 ± 14 
% HIV -specific lysist 
Total 12-27 19 ± 4.9 17-54 32± 13 12-45 26 ± 12 
CD28-negative 0.0-10 4.8 ± 3.5 10-41 22 ± 11 14-50 26 ± 13 
*Group 1 is composed of subjects with HIV-specific CTL that are predominantly CD28+, 
group 2 of subjects with both CD28+ and CD28- CTL and group 3 of subjects with 
predominantly CD28- CTL. 
tvirus load is expressed as log10 HIV RNA copies/ml plasma. 
tThe mean ± SD and range of% HIV -specific lysis for each group at an E:T ratio of 50: 1 
is shown for both unmanipulated (total) and CD28+ T cell-depleted (CD28-negative) 
effector cell populations. 
131 
significant correlations between the percentage of CD28- anti-HIV CTL and CD4+ T cell 
counts (r = -0.52, p<.01), CD4:CD8 ratio (r = -0.55, p<.01) and HIV plasma virus load (r 
= 0.64, p<.001). Figure 2a-c graphically shows the relationship between the relevant 
parameters and percentage of CD28- anti-HIV CTL with the line of best fit superimposed 
over scatter plots. The lack of a statistically significant relationship between the 
proportion of circulating CD8+ T cells that were CD28+ and the predominant CD28 
phenotype of restimulated anti-HIV CTL suggests that accumulation of CD8+CD28- T 
cells in the peripheral blood of HIV -infected individuals does not simply reflect 
activation of anti-HIV CTL. 
4.4.3 TCR ~ chain V gene family expression levels 
To determine whether .any differences in TCR ~ chain V gene family usage by CD28+ 
and CD28- T cells were associated with the different cytotoxicity patterns, we compared 
CD8+CD28+ and CD8+CD28- T cells by RT-PCR. For most of the 14 individuals whose 
CD8+ T cells were analyzed, a pattern similar to figure 3a was evident, in that 1 or 2 
families within the CD8+CD28- population were expanded compared to their CD8+CD28+ 
counterparts. The affected families differed between individuals such that overall there 
was very little difference between CD28+ and CD28- expression levels of each TCR~V 
family (figure 3b). Only relative TCR~V9 levels differed significantly when the mean 
TCR~V family levels for all 14 individuals were compared (11. 7% for CD28+, 18.1% for 
CD28-, p<0.01). 
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Figure 2. Correlation between percentage CD28 negative anti-HIV CTL and markers of 
HIV disease activity and progression. Scatter plots of percentage CD28 negative anti-HIV 
CTL versus CD4+ T cell counts/pi peripheral blood (a), CD4/CD8 T cell ratios (b), and 
Log10 plasma HIV load (c) are shown together with the line of best fit in each case. 
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Figure 3. (a) RT PCR analysis ofthe 24 TCRPV gene families for CD8+CD28-(top) and 
CD8+CD28+ (bottom) T cells from 1 representative HIV-infected subject. (b) Mean relative 
TCRPV family expression levels(± standard deviation) for cns+cD28+ (dark bars) and 
CD8+CD28- (light bars) T cells from 14 HIV -infected subjects. The intensity of each pv 
band was expressed as a percentage of the aC control band intensity for standardization 
and inter-individual comparison of relative TCRPV intensity levels. 
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Since HIV -specific CTL analysis revealed strong associations between the CD28 
phenotype of CTL and several parameters related to disease progression, we wanted to 
determine whether individuals with low CD4+ T cell counts and high levels of virus 
replication showed greater variability in TCR~V family expression levels between 
CD28+ and CD28- T cells compared to subjects with higher CD4+ T cell counts and 
undetectable levels of virus replication. Five of the 14 individuals analyzed had <200 
CD4+ T cells/I-ll blood and >4.5 log10 copies HIV RNA/ml blood, while another 5 had 
>300 CD4+ T cells/!J.l blood and undetectable levels of virus replication. Within the 
former group, only TCR~V6 differed significantly between CD28+ and CD28- T cells 
(27.4% and 40.9% respectively, p<O.Ol), while the levels of none of the 24 TCR~V 
families differed significantly for subjects in the latter group. 
For a more detailed examination of the TCR repertoire, junctional length diversity 
analysis within 7 TCR~V families was performed. In all cases tested, the CD8+CD28+ T 
cells showed the typical intrafamily distribution pattern of 5-7 bands with central bands 
the most intense21 . In contrast, length polymorphism ~ithin the expressed TCR~V genes 
of the CD8+CD28- T cells was lesser in many instances, with fewer individual bands 
visible and a skewed intensity pattern compared to the standard normal distribution 
(figure 4). Of 10 subjects tested, 8 had perceptible intrafamily TCR~V differences 
between CD28+ and CD28- T cells for at least one family. However, the extent of the 
observed differences did not appear to be associated with either disease stage or the 
CD28 phenotype of anti-HIV CTL. 
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Figure 4. TCRPV gene intrafamily junctional length diversity analysis of CD8+CD28+ 
(+)and CD8+CD28-(-) T cells. Products from 3 TCRPV families {PV5, PV6, PV8) of 
2 representative HIV-infected subjects (a and b) separated on sequencing gels and 
visualized by silver staining are shown. 
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4.4.4 Intracellular cytokine analysis 
To investigate potential functional differences between CD8+CD28+ and CD8+CD28- T 
cells related to cytokine production, both unmanipulated and CD28- T cell populations 
were tested for IL-2 and IFN-y production in response to PMA/ionomycin stimulation. 
Both cytokines were produced to some extent by CD28+ and CD28- T cells for each of 9 
subjects studied. One representative example is shown in figure 5. 
Three of the 9 subjects tested had <200 CD4+ T cells/j..tl blood and high levels of virus 
replication, while virus replication was suppressed below detectable levels and CD4+ T 
cell counts were >400 cells/f.!l blood for the other 6 individuals. Table 2 shows the range, 
i 
mean, and standard deviation of the percentage of PMA/ionomycin stimulated CDS+ T 
cells secreting IL-2 and IFN-y for both total PBMC and CD28- PBMC populations in 
these 2 groups. Although it seemed apparent that fewer CD28- cells from individuals 
with low CD4 counts secreted IFN-y than those of subjects with higher CD4 counts, this 
difference was not statistically significant when mean values were compared. The 
number of cells secreting IL-2 also did not differ between the 2 groups. Both 
CD8+CD28+ and CD8+CD28- T cells produced IFN-y and IL-2 in response to 
PMA/ionomycin stimulation. 
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Figure 5. Intracellular flow cytometry results for IL-2 (middle panels) and IFN-y (lower 
panels) production by unmanipulated (left) and CD28-depleted (right) PMA-stimulated 
PBMC. The upper panels show isotype matched negative controls. We gated on CD8+ 
cells for analysis and only CD8 high cells are shown in the flow cytometry plots to 
exclude cns+cn28· natural killer cells. 
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Table 2. IL-2 and IFN-y production from T cells of individuals with and without 
characteristics of progressive HIV infection 
3 subjects with low CD4 counts 6 subjects with high CD4 counts and 
and high levels of virus replication undetectable virus replication 
IL-2 IL-2 IFN-y IFN-y IL-2 IL-2 IFN-y IFN-y 
Total* CD28-t Total CD28- Total CD28- Total CD28-
Range(%) 2-4 2-5 4-19 4-11 2-15 2-11 7-50 4-49 
Mean± SD 3 ± 1 4 ± 1.5 11±8 7± 4 6 ± 5 4± 3 25 ± 17 21 ± 16 
*Total refers to unrnanipulated PBMC. 
t CD28- refers to PBMC depleted of CD28+ cells. 
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4.5 Discussion 
Both the number and proportion of CD8+ T cells lacking surface CD28 expressiOn 
increase dramatically during HIV infection3-6. To explore the possibility of a relationship 
between expansion of this subset and the CD8+ T cell dysfunction that parallels disease 
progression, we determined the predominant CD28 phenotype of HIV -specific CTL from 
individuals at various · stages of chronic infection. Three patterns were readily 
distinguishable. Anti-HIV CTL were either predominantly CD28+, more or less equally 
distributed between CD28+ and CD28- subsets, or predominantly CD28-. There were 
substantial differences in various immune parameters compared between these 3 groups 
of HIV -infected subjects distinguished on the basis of the predominant CD28 phenotype 
of their anti-HIV CTL. Mean CD4+ T cell numbers and mean CD4+/CD8+ T cell ratios 
. 
progressively decreased as the predominance of CD28- anti-HIV CTL increased in groups 
1 through 3. Conversely, HIV replication levels progressively increased in groups 1 
through 3 in parallel with increasing predominance of CD28- anti-HIV CTL. We also 
observed significant inverse correlations between the percentage of anti-HIV CTL that 
were CD28-, CD4+ T cell counts and CD4+/CD8+ T cell ratios. There was a highly 
significant direct correlation between the percentage of anti-HIV CTL that were CD28-
and HIV plasma virus load levels. Since CD4+ T cell numbers, CD4+/CD8+ T cell ratios, 
and virus load are related to HIV disease stage and/or activity, this data indicates that the 
CD28 phenotype of anti-HIV CTL also reflects HIV disease stage and activity. Thus, as 
has been previously reported for the circulating CD8+ T cell population as a whole, the 
predominance ofCD28- anti-HIV CTL parallels disease progression22. 
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To investigate the possible basis for the observed association between HIV disease stage 
and CD28 phenotype of anti-HIV CTL, we compared CD8+CD28+ and CD8+CD28- T 
cells at different stages of HIV disease in terms of their TCR~V repertoire diversity and 
cytokine production profile. We speculated that if disease progression directly related to 
the accumulation of CD28- CTL, decreased diversity in the TCR~V repertoire and/or 
defective cytokine production within the CD28-CD8+ T cell subset of individuals with 
more advanced disease could be involved. For examination of TCR~V diversity, both 
inter and intrafamily diversity was studied. At the family level, most individuals 
demonstrated selective CD28- T cell expansions within one or 2 families, regardless of 
disease stage. Since the affected families differed between individuals, no overall 
difference was detected between CD28+ and CD28- TCR~V family expression levels. 
However, since the methodology utilized was semi-quantitative and addressed the CD8+ 
T cell repertoire as a whole rather than the HIV -specific repertoire, it is possible that a 
fully quantitative more targeted approach might detect differences between CD28+ and 
CD28- TCR~V family expression levels for individuals at different stages of disease 
progressiOn. 
When intrafamily junctional length diversity was assessed, the CD8+CD28- cells often 
showed less diversity and/or a skewed distribution pattern compared to their CD8+CD28+ 
counterparts. However, there was again no notable difference in the extent of CD28- T 
cell junctional length diversity observed between individuals at early or more advanced 
stages of disease. These data indicate that, at family and intrafamily levels, TCR~V 
repertoire diversity is maintained at roughly normal levels for both CD28+ and CD28- T 
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cells, regardless of disease stage and/or CD28 expression of HIV -specific CTL. It should 
be noted that TCR~V diversity analysis was also assessed on the total CD8+ T cell 
population and these results don' t necessarily reflect what is occurring in the HIV-
specific CTL population. In any case, our results are consistent with the CD8+CD28- T 
cells representing that fraction of the entire CDS+ T cell repertoire either currently or 
previously activated and recruited into the effector cell population. Previous studies 
showed that the dense ol'igoclonal bands within the CD28- population were comprised of 
a dominant clone also present in the CD28+ population16. 
We also examined IFN-y and IL-2 production by CD28+ and CD28- T cells stimulated 
with PMA/ionomycin and found that both subsets secreted these cytokines, regardless of 
disease stage. The percentage of CD28- T cells from individuals with advanced disease 
producing IFN -y after ,stimulation appeared to be considerably less than from individuals 
at earlier stages of disease, however, this difference was not statistically significant. 
Production of IL-2 by CD8+CD28- T cells was low for all individuals studied with no 
differences observed on the basis of disease stage. 
The results of this study demonstrate an association between accumulation of CD28-
HIV -specific CTL and disease progression. Mechanistically, this association cannot be 
readily attributed to disease related degeneration of CD8+CD28- T cells in terms of either 
their TCR~V family repertoire diversity or ability to produce relevant cytokines such as 
IFN-y or IL-2. The expanded CD28- T cell population in HIV infection consists at least 
partly of activated, effector anti-HIV CTL and identical expanded clones occur within 
both CD28+ and CD28- subsets 13' 1 ~. This suggests that for the most part, CD8+CD28+ and 
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CD8+CD28- T cells in peripheral blood are phenotypic variants of the same population, 
with the CD28- effector T cells being recruited from CD28+ precursors and accumulating 
due to unresolved antigenic stimulation17. Several investigators reported that CD28- T 
cells are anergic, which can be reversible, while others reported that loss of CD28 
expression reflects telomere shortening and is one of the main genetic alterations 
associated with irreversible growth arrest6'8' 10. Therefore, at any particular time point in 
HIV infection, the CD8t CD28- T cell population should be comprised of effector cells 
engaged in the ongoing immune response and senescent or "spent" cells left over from 
past responses. As disease progresses, we would expect the mixture to represent more 
I 
spent cells and fewer effector cells. The increasing predominance of CD28- anti-HIV 
CTL that we observed in parallel with disease progression suggests that recruitment from 
the CD28+ population has limits, but the character of the CD8+CD28- T cells as reflected 
. 
by TCR~V repertoire diversity or ability to produce IFN-y and IL-2 didn't change 
significantly with disease progression. The lack of apparent changes in repertoire 
diversity may reflect rapid turnover of the CD28- population driven by HIV replication at 
all stages of chronic HIV infection. In this case, although individual clones within the 
CD28- population would continuously evolve, overall diversity could remain fairly 
constant. The ability of CD8+CD28- T cells to produce IFN-y is well recognized for 
activated effector cells, but a decreased capacity for cytokine production with advanced 
disease might be expected if this were associated with a shift to a more predominantly 
spent CD8 population23 . No significant decrease in IFN-y production by CD8+CD28- T 
cells from individuals with advanced disease was observed. However, we used a highly 
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potent stimulus bypassing the role of surface molecule engagement, rather than antigen-
specific stimuli, which could also explain the unexpected IL-2 production by CD8+CD28-
T cells4 . However, even if nominal antigenic stimulation is an insufficient trigger, this 
demonstrates that CD8+CD28- T cells can produce IL-2. 
In summary, we found a clear relationship between HIV disease progression as measured 
by CD4+ T cell counts, HIV disease activity as measured by virus load, and the 
proportion of HIV -specific CTL expressing CD28. As HIV disease progresses and viral 
replication increases, the HIV -specific CTL response appears to become stressed and 
eventually spent in terms of its ability to recruit new effector cells from the CD8+CD28+ 
I 
T cell population. Our data also indicate that the relationship between HIV disease 
progression and accumulation of CD8+CD28- T cells reflects the stress imposed on the 
immune system by HIV rather than a characteristically dysfunctional CDS+ T cell 
response. This suggests that effective immune responses retain a reserve of potential 
effector cells within the CD8+CD28+ T cell population, whereas ineffective responses 
inexorably shift to CD8+CD28-predominance. 
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5.1 Abstract 
Introduction: To identify factors associated with loss of in vitro stimulated anti-HIV 
CTL activity, we compared immunological, virological and other characteristics of one 
group of individuals who sustained anti-HIV CTL activity for prolonged periods with 
viral replication suppressed below detectab-le levels to another group that lost anti-HIV 
CTL activity under the same circumstances . 
. 
Methods: Forty-four individuals, all but 1 receiving HAART or combination therapy, 
were followed up to 56 months. Virus load, lymphocyte counts, CD28 expression on 
CD8+ T cells, in vitro restimulated HIV -specific CTL and T cell proliferation were 
assessed at regular intervals. 
Results: Twenty individuals with consistently detectable HIV replication and 17/24 
. 
individuals with sustained suppression of HIV replication maintained anti-HIV CTL 
responses throughout. As a group, the 7 who lost anti-HIV CTL were older, had weaker 
baseline anti-HIV CTL activity, higher historical virus loads, lower historical and 
contemporary CD4+ T cell counts and a lower percentage of CD8+ T cells expressing 
CD28. Multivariate analysis suggested CD4+ T cell counts and anti-HIV CTL amplitude 
at study onset were independently associated with CTL loss in these 7 individuals, as was 
percentage of CD8+ T cells expressing CD28 at study' s end. There was a significant 
direct correlation between nadir CD4+ T cell counts and duration of anti-HIV CTL 
persistence after suppression of viral replication. 
Conclusions: Most HIV -infected individuals retain CD8+ anti-HIV CTL with in vitro 
proliferative potential, even when · antigen is limited. Those who lose HIV -specific CTL 
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responses generally show past or cunent evidence of severe disease progresswn or 
activity. 
Keywords: Immune memory, Cytotoxic T lymphocytes, Virus load, HAART 
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5.2 Introduction 
Anti-HIV CTL are critical for immune suppression of HIV replication, however, the 
initially vigorous CDS+ T cell response against HIV incompletely controls replication. 
Without effective intervention, the breadth of anti-HIV CTL activity decreases gradually 
with progressive disease [1-5]. Highly active antiretroviral therapy (HAART) is central 
to effective intervention, 'but cumulative toxicity and multi-drug resistance can limit the 
long-term success of pharmacological intervention. Therefore, improving immune 
control of HIV replication remains an important therapeutic objective. While even 
temporary pharmacological suppression should augment control of HIV replication by 
pre-existing immunity, virus loads rapidly rebound to pretreatment levels following most 
treatment interruptions J 6]. Previous studies showed that, after HAART, the frequency of 
circulating, activated HIV -specific CDS+ T cells falls rapidly in parallel with plasma HIV 
RNA [7,S]. Several studies also reported declining HIV-specific memory CTL 
frequencies [9, 1 0]. Rapid loss of activated T cells is appropriate with HIV antigen 
withdrawal, but concurrent disappearance of memory T cells suggests HIV -specific 
defects. In this context, a distinct distribution pattern of cell surface CCR7, CD27, and 
CD45RA reported for HIV versus cytomegalovirus (CMV)-specific CDS+ T cells 
indicates selective accumulation of immature HIV -specific memory cells [ 11-13]. Both 
antigen presenting cell and CD4+ helper T cell abnormalities could contribute to defective 
generation of HIV -specific CDS+ T cells, but more research is needed for a better 
understanding of factors affecting evolution of HIV -specific memory CTL during 
effective antiretroviral therapy [14, 15]. 
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To address this need, we monitored anti-HIV CTL activity and a number of potentially 
related factors in 44 HIV-infected individuals with different patterns of HIV replication. 
Individuals with advanced HIV infection, as previously defined by extremely low T cell 
counts, were excluded as anti-HIV CTL activity would be undetectable in part of this 
population at study onset [3 ,4]. The individuals included varied considerably with 
respect to extent of immune degeneration occurring before treatment, efficacy of their 
antiretroviral treatment ·and extent of immune reconstitution that followed treatment. 
Anti-HIV CTL activity persisted in all individuals with sustained detectable HIV 
replication and in most individuals with prolonged (>4 years) suppression of HIV 
replication to undetectable levels. However, about 113 of individuals with prolonged 
periods of undetectable plasma HIV RNA lost all anti-HIV CTL activity. To identify 
factors predisposing t? this loss, we compared the group of individuals who lost HIV-
specific memory CTL activity to those who retained their HIV -specific CTL over 
prolonged periods of effective antiretroviral therapy. This revealed immunological, 
virological and other factors associated with loss of HIV -specific CD8+ CTL following 
suppression of HIV replication to undetectable levels. 
154 
5.3 Materials and Methods 
5.3.1 Study subjects 
Study participants were recruited through the Infectious Disease Clinic of the St. John's 
General Hospital, St. John's, NL, Canada. Clinic visits were scheduled at approximately 
3 month intervals or more often as necessary for appropriate clinical care. In conjunction 
with each visit clinical evaluation was performed, plasma HIV RNA was measured using 
Amplicor HIV-1 Monitor™ kits (Roche Diagnostic Systems Inc., Mississauga, Ontario, 
Canada) and peripheral blood lymphocyte (PBL) subsets were assessed by flow 
cytometry. Ethical approval was obtained from the Memorial University Faculty of 
Medicine Human Investigation Committee and all participants provided informed consent 
for blood collection an~ access to clinical and laboratory records. 
5.3.2 Sample preparation 
Peripheral blood mononuclear cells (PBMC) were isolated from acid-citrate dextrose 
(ACD)-preserved fresh whole blood by density gradient centrifugation with Ficoll-paque 
lymphocyte separation medium (Pharmacia Chemicals, Dorval, Quebec, Canada). 
PBMC were washed twice in phosphate-buffered saline (PBS) containing 1% fetal bovine 
serum (FBS; Gibco, Grand Island, New York, USA), resuspended in lymphocyte medium 
(RPMI 1640 with 10% FBS, 10 mM Hepes, 2 mM L-glutamine, 1% 
penicillin/streptomycin, and 2x 1 o-5 M 2-mercaptoethanol; all from Gibco) and counted. 
Human leukocyte histocompatibility antigen (HLA) class I typing and generation of B 
lymphoblastoid cell lines (BLCL) were done as previously described [ 4]. 
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5.3.3 Cytotoxicity assays 
To activate anti-HIV CTL, approximately 1x107 PBMC were stimulated by an 
autologous mixed lymphocyte reaction (AMLR) as previously described [4]. HIV-
specific CTL activity was assessed against autologous or HLA-matched BLCL targets 
infected with the following recombinant vaccinia viruses: vDK1 (gag) , vCF21 (pol) , 
vPE16 (gp160), vTFnef(nej), and vSC8 (E. Coli ~-galactosidase, control) (all from the 
NIH AIDS Research arrd Reference Reagent Program, Rockville, Maryland). Target 
cells were infected with 15 plaque forming units (pfu)/cell of the desired virus overnight, 
labeled for 90 minutes with 100 !J.Ci Na251Cr04 (Amersham Life Sciences, Arlington, 
IL), washed 4 times with PBS containing 1% FBS, counted, and resuspended m 
lymphocyte medium. Effector and target cells (5000 cells/well) were incubated m 
duplicate in 96-well cu}ture plates in a final volume of 300 !J.llwell at effector:target (E:T) 
ratios of 50:1, 25:1 , and 12.5:1. Minimum and maximum release wells contained targets 
in medium alone or IN HCl respectively. After 5 hours incubation, 100 !J.l supernatant 
was removed and counted in a Wallac 1480 gamma counter. Percent killing was 
determined by the formula: 
(test 51 Cr release - spontaneous release) x 100 
maximum 51Cr release- spontaneous 51Cr release 
Spontaneous 51Cr release was always <25% of maximum 51Cr release and results were 
considered positive when % specific 51 Cr release in the test wells was 2 10% above 
controls. 
156 
5.3.4 Flow Cytometry 
To determine the proportion of CD8+ T cells expressing CD28, PBMC were washed in 
PBS with 5 mM EDTA and 0.1% bovine serum albumin (BSA; Sigma Chemical Co., St. 
Louis, Missouri, USA) and incubated for 20 minutes at 4°C with fluorescein 
isothiocyanate (FITC)-conjugated anti-CD3 (Dako Diagnostics, Mississauga, Ontario, 
Canada), phycoerythrin (PE)-conjugated anti-CD28 and Peridinin Chlorophyll Protein 
(PerCP)-conjugated anti-CD8 (Becton Dickinson, Mississauga, Ontario, Canada). 
Samples were then washed, resuspended in 0.5% paraformaldehyde in PBS and analyzed 
on a F ACStarPlus flow cytometer (Becton Dickinson) after excitation at 488 nm. 
5.3.5 Proliferation assays 
Lymphocyte proliferati.on assays were carried out by resuspending PBMC in lymphocyte 
medium with 10% human AB serum (ICN Biomedicals Inc., Aurora, Ohio) replacing 
FBS. Cells were incubated at 1x105/well in triplicate in 200 fll medium in 96-well 
culture plates. Negative control wells included 2 f.!g/ml ~-galactosidase (VWR Canlab, 
Mississauga, ON) or medium alone, while positive control wells contained 5 !J,g/ml 
purified phytohemagglutinin (PHA-P; ICN Biomedicals Inc.). Test wells contained 2 
f.!g/ml Candida albicans antigen (Greer Laboratories Inc., Lenoir, NC) or HIV p24 
(Virogen, Watertown, MA). After 5 days, wells were pulsed with 1 f.!Ci 3H-thymidine 
(Perkin Elmer Life Sciences Inc. , Boston, MA), for 16 hours. The cells were then 
harvested onto filter mats using a Tomtec Harvester96 and counted on a Packard 
TopCount beta counter. Stimulation indices (SI) were determined by dividing 3H-
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thymidine incorporation in test wells by 3H-thymidine incorporation in negative control 
wells. AnSI >5 was considered a positive response. 
5.3.6 Statistical Analyses 
Normal distribution of numerical data was confirmed by the Kolmogorov-Smimov test. 
Significant differences in mean values of parameters compared between groups were 
assessed by one way ANOVA. Fisher' s exact test was used to assess associations and 
linear regression was used to assess correlation between parameters. All univariate 
statistical analyses were done with SPSS for Windows, version 9 (SPSS Inc.) and had a 
I 
power of at least 80%. A binary logistic analysis with both forward and backward 
conditional stepwise regression was used to evaluate variables independently associated 
with loss of HIV -specific CTL. 
. 
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5.4 Results 
5.4.1 Subject Characteristics 
Forty-four HIV-infected individuals were included in this study. These individuals fell 
into 2 groups based on viral replication over the study period. Twenty had detectable 
plasma HIV RNA throughout (group 1 ). Of these individuals, 17 were receiving 
HAART, with 10 on protease inhibitor (PI)-based regimens and 7 on non-nucleoside 
reverse transcriptase inhibitor (NNRTI)-based regimens. Two received dual combination 
therapy with nucleoside analogue RT inhibitors (NRTI) and one subject was treatment 
na'ive. In most cases, virus loads fluctuated around 1x104 copies/ml plasma during the 
study, but several individuals consistently maintained virus loads above 1xl05. Twenty-
four subjects maintained undetectable plasma HIV RNA throughout (group 2). Eighteen 
of these individuals received PI-based HAART, 3 received combination therapy with 2 
NRTis and 4 received combination therapy with 3 NRTis. Table 1 compares basic 
characteristics of the 2 groups. The group without detectable virus replication had 
significantly more CD4+ T cells at both early (average ·of first two clinic visits following 
study onset) (p = 0.01) and late (average of 2 most recent clinic visits) (p = 0.004) time 
points. However, these groups did not differ significantly with respect to gender, mean 
age, or mean CD8+ T cell counts at early or late time points (Table 1 ). All but the 
treatment na'ive individual had received dual combination therapy with NRTis prior to the 
introduction ofNNRTis and Pis. 
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Table 1. Comparison of general characteristics of groups with and without detectable 
HIV replication over the study period. 
Group 1 a (n = 20) Group 2 (n = 24) 
Parameter 12 male, 8 female 14 male, 10 female 
Range Mean± SD Range Mean± SD 
Age at study onset (years) 23-43 33.7 ± 6.8 24-49 34.5 ± 6.80 
Follow-up (months) 14-49 32 ± 12 16-56 37.0 ± 10.8 
CD4+ T cells- earll 30-812 345 ± 202 192-898 475 ± 184 
CD4 + T cells - late 43 -758 399 ± 289 259- 1474 618±215 
CD8+ T cells - early 481 - 1353 965 ± 544 254-2559 1015 ±314 
CD8+ T cells - late 463-1575 1071 ± 557 203 - 2454 968 ± 328 
aGroup 1 is composed of individuals who had detectaple HIV replication throughout the 
study. Group 2 is composed of individuals who maintained HIV replication at 
undetectable levels throughout the study. 
bAll T cell values are expressed as the number of cells/f..Ll peripheral blood. Early refers 
to the mean of each individual's values measured at the first 2 time points in the study 
while late refers to the mean of the values measured at the last 2 study time points. 
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5.4.2 HIV -specific CTL Activity 
Subjects were tested for CTL activity against HIV gag, pol, env, and nef over periods 
ranging from 14 - 56 months. At study onset, all had CTL activity against at least one 
HIV antigen. Figure 1a depicts the percentage of individuals within each group with 
CTL against each HIV antigen tested. HIV -specific CTL responses in groups 1 and 2 
were similarly distributed with regard to overall specificity. All 20 individuals in group 1 
with detectable levels of HIV replication maintained anti-HIV CTL activity throughout 
the study, compared to 17/24 subjects in group 2. Several of the 37 individuals 
maintaining anti-HIV CTL activity varied in terms of partial loss or broadening of 
activity, but responses against at least 1 HIV protein persisted throughout the study. 
HIV -specific CTL activity disappeared for 7 individuals in group 2 (group 2a). Loss of 
HIV -specific CTL a~tivity in the total study cohort was strongly associated with 
suppression of viral replication below detectable levels (p = 0.009). 
All 7 individuals who lost their anti-HIV CTL were receiving PI-based HAART. Figure 
1 b shows their pattern of HIV -specific CTL responses at baseline relative to the 17 
individuals with persistent anti-HIV CTL activity despite viral suppression (group 2b). 
The mean number of HIV proteins (out of 4 tested) recognized by CTL was lower for 
group 2a than 2b (p = .026). When the mean amplitudes of individual CTL responses 
against gag, pol, env and nef were compared between groups 2a and 2b, the mean 
amplitude of anti-gag responses was significantly lower in group 2a (p = .041). Thus, 
there was evidence of weaker baseline anti-HIV CTL responses in the group of 
individuals who lost their responses during effective antiretroviral therapy. 
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Figure 1. Comparison of anti-HIV CTL responses in different groups. Panel a compares the 
percentage of individuals with CTL against each of the indicated HIV antigens in groups with 
detectable (group 1) and undetectable (group 2) HIV replication throughout the study. Panel b 
shows the same comparison for those wi~hin group 2 who lost (group 2a) and those who 
maintained (group 2b) their HIV -specific CTL over the study period. 
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5.4.3 Factors Associated with Loss of Anti-HIV CTL Activity 
For the 7 subjects in group 2a, complete loss ofHIV-specific CTL occurred IS to 50 
months after suppression of viral replication to undetectable levels. Duration of viral 
suppression was not a critical factor as there was no significant difference in follow-up 
time between groups 2a and 2b (Table 2) and 5 subjects with the longest periods of 
controlled virus replication (51-56 months) maintained consistently strong and diverse 
anti-HIV CTL activity. To uncover factors related to the failure of certain individuals 
with controlled viral replication to maintain HIV -specific CTL activity, we compared the 
7 individuals with prolonged viral suppression who lost CTL activity (group 2a) to the 
remaining 17 individuals who maintained CTL activity despite prolonged viral 
suppression (group 2b). Table 2lists the mean, range and standard deviation (SD) of 
parameters used for comparison. The mean age of subjects who lost anti-HIV CTL 
activity was greater than that of the 17 who retained anti-HIV CTL activity (p = .01). 
Mean nadir CD4+ T cell count (including time points prior to study onset, p = .005) and 
early CD4+ T cell count (average of first 2 values after study onset, p = .005) were 
significantly lower in the group that lost anti-HIV en.: activity. While CDS+ T cell 
counts were not significantly different for these 2 groups, the CD4:CDS T cell ratio at the 
beginning (p = .029) and end (p = .023) of the study was significantly lower in the group 
that lost anti-HIV CTL activity. The percentage of CDS+ T cells expressing CD28 also 
related to maintenance of anti-HIV CTL activity. Subjects who lost HIV-specific CTL 
activity had a lower mean percentage of CDS+ T cells expressing CD2S at early and late 
time points (p = .03). Using past plasma virus load measurements, we also found that the 
group who lost anti-HIV CTL activity had experienced higher plasma HIV RNA levels 
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Table 2. Comparison of groups with and without sustained HIV -specific CTL responses 
over periods of undetectable HIV replication. 
Group 2aa n=7 Group 2b n = 17 
Treatment 
PI-based HAART 7 10 
2 NRTis 3 
3 NRTis 4 
ANOVA 
Parameter Range Mean± SD Range Mean± SD F p 
Age at study onset (years) 33-52 43 ± 7.35 2S-50 36.4 ± 5.24 6.2 0.01 
Duration viral suppression 23-45 37.7 ± 7.95 16-56 34.S ± 12 t 0.34 0.29 
Nadir CD4+ T cellsb 1S-314 160 ± 115 176-S35 336 ± 152 7.5 0.005 
CD4 + T cells - earlyc 172-4S7 310 ± 122 221-1046 551 ±211 7.9 0.005 
CD4 + T cells - late 259-757 4S3±194 439-1131 660 ± 220 3.S 0.04 
Nadir CDS+ T cells 417-1436 6S2 ± 356 163-1240 649 ± 30S 0.05 0.41 
CDS+ T cells - early 471-2S44 11S6 ± 764 254-3419 1052 ± 709 0.17 0.34 
CDS+ T cells - late 5S2-2S11 1101 ± 766 203-2795 9S5 ± 640 0.15 0.35 
Peak virus loadd 5-6 5.3 ± 0.6 3-6 4.25 ± 0.93 7.7 0.005 
%CDS+ T cells CD2S+ - early 27-44 42.4 ± 5.2 25-77 45.7 ± 15.0 4.03 0.03 
%CDS+ T cells CD2S+ - late 3S-53 42.4 ± 5.2 33-71 51.1 ± 11.3 3.7 0.03 
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aGroup 2a is composed of individuals with undetectable HIV levels throughout the study 
who lost their HIV -specific CTL activity. Group 2b is composed of individuals with 
sustained undetectable HIV replication throughout the study who maintained HIV-
specific CTL activity. 
bAll T cell values are expressed as the number of cells/~-tl peripheral blood. The nadir 
value is the lowest observed historical value including prior to study onset. 
cEarly refers to the mean of each individual's values measured at the first 2 time points in 
the study while late refers to the mean of the values measured at the last 2 study time 
points. 
dThe peak virus load value is the highest observed historical value in log10 copies of HIV 
RNA/ml plasma including prior to study onset. 
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before responding to therapy (p = .005). For the 7 individuals who lost HIV -specific 
CTL activity, there was a significant direct correlation between nadir CD4+ T cell counts 
and duration of anti-HIV CTL persistence after viral replication was suppressed to 
undetectable levels (r = .889, p = .007; fig. 2a). There was a weaker inverse correlation 
with nadir CD8+ T cell counts (r = -.781, p = .038; fig. 2b) and no significant correlation 
with any other parameter measured. Together, these factors outline a profile 
characterized by older age, more extensive previous disease progression and 
susceptibility to more rapid disease progression that reflects a limited capacity to 
maintain anti-HIV CTL activity in the absence of detectable replicating virus. 
, 
Multivariate analysis was carried out to evaluate which factors were independently 
associated with loss of anti-HIV CTL. Binary logistic regression demonstrated that early 
CD4+ T cell counts (p = .03), anti-HIV CTL amplitude at study onset (p = .04) and the 
percentage of CD8+ T cells expressing CD28 at late time points (p = .03) independently 
associated with loss of anti-HIV CTL (Table 3). The small sample size (n = 7) of the 
group who lost anti-HIV CTL limits the power of this test to exclude the factors not 
found to be independently associated with loss of anti-HIV CTL. 
5.4.4 CD4+ T Cell Function 
To test whether the association between CD4+ T cell numbers and persistent anti-HIV 
CTL activity reflected particular CD4+ T cell functions, we measured T cell proliferation 
against PHA, Candida, and HIV p24 for 39 individuals. Figure 3a shows that all had 
proliferative responses to PHA with fewer responses against Candida and even fewer 
against HIV p24. Figure 3b shows the frequency of proliferative responses for group 2 
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Figure 2. Relationship between nadir T cell counts, suppression of virus load to 
undetectable levels, and disappearance ofHIV-specific CTL with proliferative 
potential. Scatter plots of the time HIV -specific CTL, following in vitro stimulation, 
persisted once HIV replication was suppressed below detectable levels, versus nadir 
CD4+ T cell counts (panel a) or nadir CDS+ T cell counts (panel b) are shown for the 
7 individuals in group 2a who lost HIV -specific CTL activity. The line of best fit is 
shown in each case. 
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Table 3. Multivariate analysis of factors associated with anti-HIV CTL loss 
Variable Odds Ratio (95% CI) p value 
CD4+ T cells- early 1.0159 (1.0008-1.0313) 0.03 
%CD8+ T cells CD28+ -late 1.1698 (1.0002-1.3682) 0.04 
CTL amplitude 1. 0920 ( 1. 0152-1 .17 4 7) 0.03 
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(HIV replication suppressed to undetectable levels) expressed separately for the 7 
individuals who lost CTL activity (group 2a) and for 14 of the individuals who 
maintained memory CTL activity (group 2b ). Although it is noteworthy that none of the 
7 individuals who lost CTL activity had proliferative responses to HIV p24, this was not 
significantly different from the frequency of p24-specific proliferation in any of the other 
groups. Therefore, we found no significant association between maintenance of HIV-
specific CD8+ CTL responses and HIV-specific CD4+ T cell responses. 
169 
a I III Group 1 D Group 21 
b I IT1 Group 2a D Group 2b I 
PHA Candida lllVp24 
Figure 3. T cell proliferation responses in different groups. Figure 3a compares the 
percentage of individuals in groups 1 (detectable HIV replication) and 2 (HIV 
replication suppressed below detectable levels) with CD4+ T cell proliferation 
(SI >5) against PHA, Candida, and HIV p24. Figure 3b compares the same T cell 
responses in group 2 individuals who either lost (group 2a) or maintained (group 
2b) HIV -specific CTL activity throughout the study. 
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5.5 Discussion 
We investigated evolution of HIV-specific CTL in one group with persistent HIV 
replication and another group with sustained undetectable HIV replication. Everyone 
with detectable viral replication maintained anti-HIV CTL through up to 4 years of 
follow-up. This indicates that with chronic antigen stimulation HIV -infected individuals 
generally maintain anti-HIV CTL, at least until advanced infection. Most individuals 
with effective viral suppression also maintained anti-HIV CTL activity, indicating 
generation of stable HIV -specific CD8+ T cell memory. The minority who lost anti-HIV 
I 
CTL activity with effective HIV suppression may bear a specific defect affecting 
generation of stable CD8+ T cell responses. It is important to understand the nature of 
this defect and any impact it may have on treatment options. 
Factors we found associated with this defect reflected either duration of HIV infection or 
extent of disease progression. The group with defective CD8+ T cell memory were older, 
had weaker baseline anti-HIV CTL activity, fewer CD4+ T cells, a lower percentage of 
CD8+ T cells expressing CD28, lower nadir T cell ·counts and higher historical HIV 
replication levels. An increasing immunological deficit with more advanced disease is 
expected, but the lingering relationship between defective CD8+ T cell memory, nadir T 
lymphocyte counts and historical virus loads is more complex. There was a highly 
significant direct correlation between nadir CD4+ T cell count and time to HIV -specific 
CTL loss. This suggests that past disease progression, reflected by nadir CD4+ T cell 
counts, can have more relevance to certain immunological functions than current disease 
status, reflected by contemporary CD4+ T cell counts. Previous findings that lower nadir 
171 
CD4+ T cell counts are associated with persistent T cell proliferation defects, prolonged 
immune activation and weaker vaccine responses following HAAR T confirm lingering 
effects of past disease progression [16-18]. While HAAR T -related immune 
reconstitution restores protection against opportunistic pathogens common in advanced 
HIV infection, HIV -specific helper T cell responses are not restored with similar kinetics 
[19]. There may be a finite window period during which HIV replication must be 
effectively addressed te preserve HIV -specific T cell responses [20,21]. Selective 
depletion of HIV -specific CD4+ T cells is also consistent with an immunological burden 
of past disease progression beyond what current CD4+ T cell counts appear to indicate 
f 
[22]. This may be an important consideration in basing the safety of treatment 
interruptions on return to baseline CD4+ T cell counts when substantial drops in CD4+ T 
cell count precede treatment resumption [23] . 
Several lines of evidence indicate that antigen-specific CD4+ helper T cells contribute to 
anti-HIV CTL responses [24,25]. Introducing HAART during acute infection preserves 
HIV -specific CD4+ T cell proliferation, which is associated with higher HIV -specific 
CTL frequencies [20]. In addition, individuals with limited HIV disease progression 
maintain strong HIV-specific CD4+ and CD8+ T cell responses [26] . Thus, early loss of 
HIV -specific CD4 + T cells may be an important determinant of disease progression and 
HIV -specific CTL loss during effective antiretroviral therapy may reflect previous loss of 
HIV -specific helper T cells. In our study, individuals who lost HIV -specific CTL 
responses were uniformly negative for HIV -specific T cell proliferation. However, only 
2/20 individuals with chronic HIV replication who retained HIV -specific CD8+ T cell 
responses had detectable HIV -specific CD4+ T helper cells. This supports the suggestion 
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of Wodarz et al. that CTL responses persist without antigen while helper T cells are 
present, but require high levels of antigen to persist without helper cells [27]. Persistence 
of anti-HIV CTL with detectable viral replication in the absence of HIV -specific helper T 
cells may involve continuous generation of effector cells without replenishing the 
memory cell pool. Continuous recruitment of memory and na'ive T cells into the 
terminally differentiated effector population with limited proliferative potential is 
consistent with the higher proportions of CD28- CDS+ T cells in individuals with chronic 
HIV replication [28,29]. 
The stability of HIV -specific CTL responses may impact on any potential utility of 
I 
treatment interruption in several ways. Firstly, individuals who lose HIV -specific CTL 
activity on HAART should suffer more rapid and deleterious changes with treatment 
interruption. Even those HIV -infected individuals retaining anti-HIV CTL activity 
respond less vigorously to viral rebotmd than to primary infection [30]. Nonetheless, a 
rise and fall of HIV levels following treatment interruption suggests useful reengagement 
of the immune system, presumably favoured in individuals retaining anti-HIV CTL [31]. 
Secondly, the usefulness of stimulating unstable immunity against HIV by treatment 
interruption would be limited. Individuals who lose anti-HIV CTL activity on HAART 
appear less likely to generate stable CTL responses with treatment interruption and less 
likely to benefit. Therefore, robust anti-HIV CTL responses may identify individuals 
most likely to benefit from treatment interruptions. Conversely, weakening anti-HIV 
CTL activity might identify individuals requiring immunological conditioning to benefit 
from treatment interruption. More studies comparing individuals with stable versus 
transient anti-HIV CTL activity are needed to clarify the role of HIV -specific CD4+ T 
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cells, antigen-presenting cell status and other factors in generating stable CD8+ T cell 
responses. 
In summary, there is a clear discrepancy in some HIV -infected individuals between the 
ability to generate anti-HIV CTL and the ability to maintain them over prolonged periods 
of undetectable viral replication. The inability to maintain anti-HIV CTL is associated 
with historical or current progression to more advanced disease. Therefore, in some 
respects historical disease progression may be equally as relevant to anti-HIV immune 
status as current T lymphocyte counts. 
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CHAPTER6 
General Summary and Discussion 
6.1 Preface 
The work described in this thesis sought to further elucidate the biological relevance of 
anti-HIV CTL. Defining the precise role of antigen-specific CTL in HIV infection has 
proven problematic. While it is now generally accepted that anti-HIV CTL play a key 
role in controlling disease progression, it is also clear that multiple mechanisms 
contribute to their failure to indefinitely control virus replication. The experiments 
conducted in this thesis addressed possible mechanisms responsible for the ultimate 
failure. 
The thesis basically involved two major studies. In the first, we performed a detailed 
examination of the CD8+ T cell population persisting through the advanced stages ofHIV 
infection. This study yielded intriguing results regarding the longevity and CD28 
phenotype ofHIV-specific memory CTL. For individuals with advanced HIV infection, 
anti-HIV memory CTL were predominantly CD28-, and were detectable only when 
replicating virus was detectable. To address these issues further, the remainder of the 
project focused on examining HIV-specific memory CTL responses within a large group 
of chronically infected individuals at various stages of disease. 
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Most of the experimental details and results have been summarized in the four 
manuscripts presented as chapters 2-5. In the ensuing sections of this chapter the overall 
significance of the information gained through these studies will be discussed. 
6.2 CDS+ T Cells in Advanced HIV Infection 
When this study was initiated it was uncertain whether normal functional attributes of 
CD8+ T cells persisted through the advanced stages of HIV infection. It was known that 
circulating HIV -specific CTL activity declined in parallel with disease progression, but it 
was unclear whether the same was true for anti-HIV CTL precursors (1). We examined 
CD8+ T cells from individuals with advanced HIV infection in terms of functional ability, 
HIV -specific CTL activity, and TCRPV repertoire diversity. Our data clearly showed 
. 
that CD8+ T cells from advanced stage individuals proliferated and differentiated into 
functional CTL in vitro, and that TCRPV diversity was maintained. In addition, for more 
than half the subjects we studied, anti-HIV precursor CTL activity was not only 
detectable but, in some cases, was strong and diverse. 
We found circulating CTL activity to be completely absent in the group of individuals 
with advanced HIV infection, whereas it was common to all subjects at less advanced 
stages of disease. Although we expected HIV-specific circulating CTL activity to be 
undetectable, the complete absence of circulating, effector CTL was unexpected. The 
complete lack of effector CTL activity suggested that an HIV-induced, in vivo defect in 
the ability to generate an effector CTL response arises during progressive disease. The 
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precursor cells themselves were not intrinsically defective, as shown by their in vitro 
activation and differentiation into functional CTL. Therefore, the defect must lie 
elsewhere. In our opinion, low total CD4+ T cell help was the most likely explanation. 
At late stages of infection, CD4+ T cells are present in extraordinarily low numbers. 
Indeed, several individuals in our study had no detectable peripheral blood CD4+ T cells. 
Given the paucity of CD4+ help at this late stage of infection, we hypothesized that CDS+ 
T cells, though functional, were not receiving adequate activation signals for proliferation 
and differentiation. Over the course of our study, four subjects had their antiretroviral 
therapy regimes modified, which resulted in control of viral replication and increasing T 
cell numbers. For these subjects, circulating CTL activity did become apparent, 
indicating that the in vivo defect in the ability to generate activated CTL can be overcome 
even after sustained p~riods of advanced infection. Surprisingly, for two individuals who 
initially showed a lack of HN -specific precursor CTL activity, this activity also became 
apparent once effective therapy was initiated. This demonstrated that the HN -specific 
CTL response was not exhausted for these subjects, as had originally been suspected. 
The findings of this study indicated that the CTL response to HN, and presumably to 
other antigens as well, is remarkably durable. Even under conditions whereby the 
immune system is exposed to persistent antigenic stimulation for extended periods, with 
deterioration of various immune components, CTL precursors persist and retain their 
normal functional attributes. In extreme circumstances, when the immune system has 
suffered severe deterioration, CTL precursors may be precluded from differentiating into 
effector CTL and performing their protective lytic function. However, this condition is 
reversible. If circumstances improve, precursors can again become activated to proliferate 
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and differentiate into circulating, effector CTL. Therefore, CTL based immunotherapy 
for HIV and other pathogens is a plausible consideration even for those individuals who 
have progressed to an advanced stage of disease. 
It is clear, however, that anti-HIV CTL do not afford lifelong protection from progression 
to AIDS. Disease progression can occur in the face of strong and diverse HIV -specific 
CTL responses (2). There were two other findings in our study of advanced stage 
individuals that we felt could shed light on reasons for the ultimate demise of the anti-
HIV CTL response. The first was the finding that, although peripheral circulating T cells 
were predominantly CD28+ for the advanced stage subjects we tested, anti-HIV precursor 
CTL were predominantly CD28-, suggesting that loss of CD28 expression on CTL might 
be associated with disease progression. The second finding was the fact that anti-HIV 
CTL responses for the four individuals who responded to therapy were transient, 
detectable only when virus was replicating and disappearing rapidly once replication was 
brought under control. This fmding indicated an inability to maintain memory CTL when 
antigen supply was limited, which conceivably would contribute to disease progression. 
We wanted to determine whether these two features were peculiar to HIV -specific CTL at 
the advanced stages of infection, or common to other phases of disease. If either (or 
both) attribute was predominant during advanced infection only, this might indicate a 
particular characteristic of anti-HIV CTL that occurs concurrent with deteriorating 
disease, and results in acceleration of disease progression. The remainder of this thesis 
project focused on examining these two attributes within a larger group of HIV infected 
individuals who were at various stages of infection. 
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6.3 A comparison of CD8+CD28+ and CD8+CD28- T cells 
We compared CD8+CD28+ and CD8+CD28- T cells within a group of 41 chronically 
infected individuals. The individuals varied considerably with respect to concurrent 
disease activity as well as cumulative disease progression, and thus, represented a broad 
cross-section ofHN disease status. 
In the first part of the study the CD28 phenotype of HN -specific CTL was determined. 
We found a strong correlation between accumulation of CD28- anti-HN CTL and 
markers of disease severity. When CD28- CTL were prevalent, viral load levels were 
high and CD4+ T cell counts were low. Conversely, for individuals demonstrating 
suppression of viral replication and higher CD4+ T cell counts, anti-HN CTL usually 
included CD28+ T c~lls. This concurred with our results for subjects with advanced 
infection, reinforcing the suggestion that accumulation of CD28- HN -specific CTL is 
associated with disease progression. 
We then compared CD8+CD28+ and CD8+CD28- T cells in terms of TCRBV repertoire 
diversity and cytokine production. We hypothesized that if disease progression was 
directly related to accumulation of CD28- CTL, this might be reflected by an altered BV 
repertoire and/or lower cytokine production output by the CD28 negative population. We 
also proposed that individuals with more advanced disease would have greater 
perturbations in their CD28- T cell subset than subjects with more limited disease 
progressiOn. 
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Although we did find CD28- T cells to have a less diverse TCRPV repertoire than their 
CD28+ counterparts, this was true for all individuals tested, regardless of disease stage. 
CD28 negative T cells produced both IL-2 and IFN-y, and the number of cells producing 
these cytokines was similar for all individuals tested. Therefore, there was no apparent 
deterioration ofthe CD28-T cell population associated with disease progression. 
In HIV infection, CD28- T cells expand during primary infection and often comprise 
more than 60% of the peripheral blood CDS+ T cell population throughout the natural 
course of disease (3). This predominance of CD28- T cells reflects continuous 
differentiation of CD8+CD28+ T cells into CD28- effector cells in response to chronic 
virus stimulation. The proportion of CD8+ T cells expressing CD28 also decreases with 
age, indicating that prolonged antigenic experience eventually leads to loss of CD28 
expression even on re:;ting memory cells ( 4). These CD8+CD28- T cells have shortened 
telomeres that signify a long history of cell division culminating in replicative 
senescence, defined as an irreversible state of growth arrest that occurs when a cell has 
undergone its finite and predictable number of cell divisions (5). Therefore, CD28- T 
cells do not represent a uniform population. Some are effector cells actively engaged in 
cell-mediated immune responses, while others are functionally effete remnants of past 
immunological battles. In our experiments, individuals with asymptomatic HIV infection 
usually demonstrated both CD28+ and CD28- HIV-specific CTL. The CD28- CTL were 
likely comprised mainly of effector cells, continuously being generated from their CD28+ 
counterparts. Individuals with progressive or advanced disease were much more likely to 
have anti-HIV CTL that were predominantly or exclusively CD28-. In these cases, we 
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propose that the detected CD28- CTL were mainly cells in a state of replicative 
senescence. This supposition is based on 2 previous findings. First, without 
corresponding CD28+ HIV -specific CTL, it is unlikely that new effector cells were being 
generated, as studies have clearly demonstrated that CD28+ T cells generate CD28-
progeny (6). Second, we detected an in vivo defect in the ability to generate effector CTL 
in individuals with advanced HIV infection. It is, therefore, highly unlikely that the 
detected CD28- CTL for these individuals represented new effectors, but rather a 
senescent population persisting after a long battle with HIV. 
In summary, we found a clear relationship between HIV disease progression and the 
I 
proportion of HIV-specific CTL expressing CD28. It appears that when uncontrolled 
virus replication occurs, HIV -specific CTL responses eventually become spent in their 
ability to recruit new ~ffector cells from the CD28+ T cell population. As a result, CD28-
CTL accumulate with progression to AIDS. 
6.4 HIV -specific Memory CTL Responses 
We performed a longitudinal study of anti-HIV memory CTL responses with a group of 
44 chronically infected individuals at various stages of disease. The individuals varied 
considerably with respect to the extent of immune degeneration that had occurred prior to 
HAAR T and the extent of immune reconstitution occurring subsequent to HAAR T. We 
observed persistent anti-HIV CTL activity in all individuals with sustained detectable 
plasma HIV RNA, and in the majority of those who responded to HAART with 
prolonged suppression of HIV replication to tmdetectable levels. None of the subjects 
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showed the same pattern of anti-HN memory CTL that we observed for advanced stage 
individuals (who were excluded from this study), ie, rapid disappearance of HN -specific 
CTL immediately following suppression of viral replication to undetectable levels. 
However, for 1/3 of the chronically infected individuals who experienced prolonged 
periods of undetectable plasma HN RNA, HN -specific CTL activity completely 
disappeared over the course of the study period. This loss occurred between 18 and 50 
months following suppression of viral replication to undetectable levels. 
When we compared various immunological and virological characteristics of individuals 
who lost HN-specific CTL activity to those who retained their anti-HN CTL over 
I 
prolonged periods of effective treatment, we found that an individual's past history of 
disease progression was the most relevant factor related to their inability to maintain 
stable HN-specific m~mory CTL responses. Nadir CD4+ T lymphocyte numbers had the 
most striking relationship to defective CDS+ T cell memory and there was a highly 
significant direct correlation between nadir CD4+ T cell counts and the duration that HN-
specific CTL activity remained detectable. When these results were examined in the 
context of our earlier results for advanced stage individuals, a pattern emerged. Subjects 
who experience periods of uncontrolled virus replication resulting in significant depletion 
of CD4+ T cells are likely to show evidence of defective CDS+ memory T cell 
maintenance, with the severity of the defect proportional to the extent of CD4+ T cell 
depletion. In our study, individuals who had progressed to advanced infection with 
extremely low CD4+ T cell counts demonstrated a complete inability to maintain anti-
HN memory cells in the absence of detectable virus. Those who had suffered significant 
but less extensive depletion of their CD4+ T cell population were able to maintain CDS+ 
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memory cells for a certain period of time, while stable HIV -specific memory CTL were 
maintained in the absence of detectable virus only for those individuals who had not 
sustained severe CD4+ T cell depletion. This data is consistent with recent evidence 
indicating that, in HIV infection, low nadir CD4+ T cell counts have prolonged effects on 
other aspects of T cell function. Persistent proliferation defects, increased T cell 
activation, and poor responses to immunization have been linked to past periods of CD4+ 
T cell lymphopenia (7 ,8,9). This suggests that long term exposure to HIV causes damage 
to the immune system that is difficult to correct. Delaying initiation of HAAR T may 
therefore result in impaired functional Immune restoration despite normalization of 
circulating CD4+ T cell numbers. 
These results indicate that the long-term quality of HIV -specific memory CTL responses 
may be markedly influenced by the specific nature of an individual's disease course, with 
a highly aggressive infection resulting in memory cells that can no longer persist in the 
absence of antigen. Significant HIV induced CD4+ T cell depletion at any time during the 
course of infection may have a negative impact on subsequent maintenance of an 
effective HIV -specific memory CTL response. This concurs with accumulating evidence 
indicating that HIV -specific CD4+ helper T cells contribute substantially to anti-HIV 
memory CTL responses (10,11). A recent study by Janssen et al confirmed the 
importance of antigen-specific helper cells in creating long-term memory CTL (12). This 
in vivo study utilized CD4-intact and CD4-deficient mice. Both sets of mice generated a 
primary response to antigen, with differentiation of CD8+ T cells into cytotoxic effectors. 
However, secondary CTL expansion was wholly dependent on the presence of helper T 
cells during priming. This indicates that CD4+ T cells are dispensable for primary 
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responses to antigen, but are absolutely required for the generation of long-term memory 
CTL. 
To determine if our data on HIV-specific memory CTL activity in humans supported the 
interpretation of Janssen's study, we examined T cell proliferation responses for the 
individuals included in our study. For subjects who lost their anti-HIV CTL when treated 
successfully with HAART, none demonstrated proliferation to HIV p24. This appears to 
support the notion that lack of antigen-specific helper T cells is associated with impaired 
long term memory CTL responses. When we examined T cell proliferation responses for 
individuals treated successfully with HAART who maintained anti-HIV memory CTL, 
slightly less than half showed proliferation to HIV -specific antigen. At first glance, this 
appeared to conflict with Janssen's study, in that stable memory CTL responses were 
apparent and, therefore, antigen-specific helper T cells should be detectable. However, 
. 
Janssen's study clearly demonstrated that secondary CTL expansion was dependent on 
the presence of T cell help during, but not after, priming. Since we tested for 
proliferation long after priming had occurred, it is entirely possible that HIV -specific 
CD4+ T cells were present during priming, but were subsequently lost. We propose that 
this group of individuals maintained HIV -specific helper T cell responses during the 
priming period, conferring on their CD8+ T cells the capacity for long term 
immunological memory. 
Recent studies have focused on investigating the mechanisms by which T cell memory is 
generated and maintained. Subsets of memory T cells have been identified based on 
expression of cell surface markers, particularly CCR7 (13). Functional differences were 
noted for these memory T cell subsets as well. Based on these findings, two functionally 
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distinct memory T cell subsets were proposed: CCR T effector memory cells and CCR 7+ 
central memory cells. When these subsets were examined in HIV- and CMV -infected 
individuals two effector memory cell subsets were distinguishable based on CD45RA 
expression (14). The HIV-specific cell pool was predominantly composed of pre-
terminally differentiated CD8+CD45RA-CCRT cells, whereas the CMV-specific pool 
consisted mainly of terminally differentiatea CD8+CD45RA+CCRT cells. High levels of 
HIV replication together with lack of adequate HIV -specific CD4+ T cell help were 
proposed to keep HIV -specific memory CD8+ T lymphocytes at the immature stage of 
CD8+CD45RA-CCRT cells, preventing their further differentiation. This skewed 
maturation of HIV -specific memory CD8+ T cells during HIV infection may have 
functional consequences for HIV pathogenesis. Indeed, in a recent study involving 
structured treatment interruption, an accumulation of pre-terminally differentiated 
(CD45RA-CCR T) CD8+ T cells was associated with viral rebounds, demonstrating that 
failure to control viremia was related to accumulation of CD8+ T cells with an immature 
phenotype (15). 
Determining the memory phenotype of anti-HIV CTL for individuals with no detectable 
antigen-specific helper T cell responses might provide a method of distinguishing 
between those who lose their HIV -specific CD4+ T cells early in the course of infection, 
resulting in defective memory CTL, and those who maintain HIV -specific CD4+ T cells 
beyond the priming period, creating an efficient memory CTL pool. This distinction 
could be useful when considering therapeutic regimes. For example, individuals who 
lose HIV -specific CD4+ T cells early during the course of infection, creating defective 
memory CTL maintenance, are more likely to experience deleterious consequences from 
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viral breakthroughs during HAART treatment, and would likely benefit from some form 
of immunological conditioning concurrent with their antiretroviral regimens. 
The current study was completed before the results discussed above were available. This 
is unfortunate, as it would have been interesting to phenotype the memory cells of the 
subjects studied here, to determine if a relationship exists between memory cell 
phenotype and persistence. It is entirely possible that individuals demonstrating loss of 
CTL activity have high numbers of non-functional, pre-terminally differentiated CD8+ T 
cells. 
In summary, our results demonstrate that individuals with detectable viral replication 
I 
maintain anti-HIV CTL activity, at least until the very advanced stages of infection. 
However, this may reflect continuous generation of effector cells in response to chronic 
antigenic stimulation, without concomitant preservation of stable memory cells. The 
majority of individuals with efficient viral suppression also maintain anti-HIV CTL 
activity, suggesting that most HIV -infected subjects generate stable HIV -specific 
memory T cells. A minority of individuals lose their HIV -specific CTL activity during 
periods of efficient suppression of viral replication, and this may indicate a specific 
defect in the ability to maintain stable memory CTL responses. Our results suggest that 
an individual's past history of disease progression, particularly as indicated by nadir 
CD4+ T cell count, may have an important impact on the longevity of their CD8+ memory 
cells. 
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6.5 Concluding remarks 
The fact that HIV disease progression can occur despite strong anti-HIV CTL responses 
undermines the importance of virus-specific CTL in controlling HIV infection. Ultimate 
failure of CD8+ T cell function should not be surprising given certain well understood 
characteristics of HIV pathogenesis. HIV can establish latent cellular infection, with 
provirus integrating directly into the host genome without concurrent expression of viral 
proteins. Thus, a persistent viral reservoir, undetectable to the immune system, is 
created. Virus and host co-exist for extended periods, with cumulative deleterious effects 
imposed upon various immune components. Anti-HIV CTL, although remarkable in 
terms of their diversity and magnitude, are low in frequency compared to the total 
number of HIV -infected cells replicating virus. The rapid rate of HIV replication, 
combined with the high error rate of reverse transcriptase, results in the generation of an 
extraordinary number of mutated virions, some of which escape CTL recognition (16,17). 
When these factors are taken into account, the ultimate failure of HIV -specific CTL 
responses is not surprising. It also becomes clear that multiple mechanisms could 
conceivably contribute to this ultimate failure. 
The results obtained from this thesis project highlight some of the mechanisms involved 
in the progressive deterioration of anti-HIV CTL responses: an in vivo defect in the 
ability to generate an effector CTL response becomes evident during the late stages of 
disease; CD28- HIV -specific CTL accumulate with chronic antigen stimulation; a defect 
in the ability to maintain stable anti-HIV memory T cells in the absence of detectable 
virus load occurs subsequent to severe CD4+ T cell depletion. All three mechanisms have 
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potential for weakening HIV-specific CTL responses. However, numerous other 
properties of HIV -specific CTL that might explain their inadequate immunoprotective 
role in HIV infection have also been identified (reviewed in chapter one). More focused 
research is required to understand the relative contribution of these diverse and 
sometimes unique mechanisms to CD8+ T cell dysfunction in HIV disease. Ideally this 
information will accelerate the development of effective vaccines and immunotherapeutic 
intervention strategies. 
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